
559 ANSWERS



0-2 REP G20=(0-1) 11-12 11-15 NODE ATTRIBUTES: **NSPEC** IS R AT 1 **NSPEC** IS R ΑT **NSPEC** IS R ΑT 3 **NSPEC** IS R AT**NSPEC** IS R 5 **NSPEC** IS R AT **NSPEC** IS R ΑT 7 **NSPEC** IS R AT **NSPEC** IS R AT 9 **NSPEC** IS C ΑT 10 **NSPEC** IS R ΑT 11 **NSPEC** IS R ΑT 12 **NSPEC** IS R ΑT 13 **NSPEC** IS R ΑT 14 **NSPEC** IS R 15 ΑT NSPEC IS R

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 16

DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

STEREO ATTRIBUTES: NONE

L3 559 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 13578 ITERATIONS

SEARCH TIME: 00.00.29

=> fil caplus

FILE 'CAPLUS' ENTERED AT 16:38:19 ON 06 JAN 96
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1996 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1967 - 6 Jan 1996 VOL 124 ISS 2 FILE LAST UPDATED: 6 Jan 1996 (960106/ED)

To help control your online searching costs, consider using the HCAplus file when using the FSEARCH command or when conducting SmartSELECT searches with large numbers of terms.

REP G20=(0-1) 11-12 11-15 NODE ATTRIBUTES: **NSPEC** IS R AT 1 **NSPEC** IS R ΑT 2 **NSPEC** IS R 3 AT IS R 4 **NSPEC** ΑT 5 **NSPEC** IS R ΑT **NSPEC** IS R ΑT 6 **NSPEC** IS R 7 ΑT **NSPEC** IS R AT 8 **NSPEC** IS R 9 ΑT **NSPEC** IS C ΑT 10 **NSPEC** IS R ΑT 11 **NSPEC** IS R ΑT 12 **NSPEC** IS R ΑT 13 **NSPEC** IS R ΑT 14 **NSPEC** IS R 15 ΑT **NSPEC** IS R AT 16 DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

L3 559 SEA FILE=REGISTRY SSS FUL L1

L5 STR



REP G20=(0-1) 11-12 11-15 NODE ATTRIBUTES: **NSPEC** IS R ΑT 1 **NSPEC** IS R AT 2 **NSPEC** IS R ΑT 3 **NSPEC** IS R ΑT 4 **NSPEC** IS R 5 AT **NSPEC** IS R ΑT 6 **NSPEC** 7 IS R ΑT **NSPEC** IS R ΑT 8 **NSPEC** IS C AT 10 **NSPEC** IS R AT 11 **NSPEC** IS R AT 12 **NSPEC** IS R AT 13 **NSPEC** IS R AT 14 **NSPEC** IS R AT 15 **NSPEC** IS R AT 16 DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

L6 536 SEA FILE=REGISTRY SUB=L3 SSS FUL L5

100.0% PROCESSED 559 ITERATIONS

536 ANSWERS

SEARCH TIME: 00.00.05

=> fil caplus

FILE 'CAPLUS' ENTERED AT 16:43:25 ON 06 JAN 96
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1996 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1967 - 6 Jan 1996 VOL 124 ISS 2 FILE LAST UPDATED: 6 Jan 1996 (960106/ED)

To help control your online searching costs, consider using the HCAplus file when using the FSEARCH command or when conducting

 $\label{lem:martSELECT} \textbf{SmartSELECT searches with large numbers of terms.}$

L7 124 L6

=> d 1-20 cbib abs hitrn

08/466,644 Page 5

- L7 AMSWER 1 OF 124 CAPLUS COPTRIGHT 1996 ACS
 1995:387946 Preparation of ([triazoly])indoly]]methylpyrrolidines as
 5-MII-like agonists. Matassa, victor Giulio; Sternfeld, Francine;
 Street, Leslie Joseph (Merck Sharp and Dohme Ltd., UK). PCI Int.
 Appl. WO 9521167 Al 950810, 22 pp. DESIGNATED SIATES: W: AM, AI,
 AU, BB, BG, BR, BY, CA, CH, CH, CZ, DE, DK, EE, ES, FI, GB, GE, BU,
 JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LY, ND, NG, NN, NN, NX, NL,
 NO, NZ, PL, PI, RD, NU, SD, SS, IJ, SK, IJ, TI, UA, US; SN: AI, BE,
 BF, BJ, CF, CG, CH, CI, CN, DE, DK, ES, FR, CA, GB, GR, IE, IT, LU,
 NC, NL, NR, NE, NL, PI, SE, SN, 10, TG. (English). CODEN: PIXXID:
 APPLICATION: NO 95-GB335 950124. PRIORITY: GB 94-2011 940202.
 AB 11tle compds. (1: R = H, C1-6 alkyl), were prepol. Thus,
 4*-(1,2,4-triazol-4-4-yl)phenylhydrazine and (25)-M-tertbutoxycarbonyl-3-(pyrrolidin-2-yl)propanal were stirred in 44 aq.
 R2504 at room temp.-reflux to give 344 I (R = H), isolated as the
 oxalate. I showed pEC50 _gtoreq.5.0 in a test of their ability to
 mediate contraction of the saphenous vein of rabbits.

 IT RN LIST MAY NOT BE COMPLETE: 135694-16-6
 171752-92-4

L7 AMSWER 2 OF 124 CAPLUS COPYRIGHT 1996 ACS (Continued) (preps. of triazole derivs. as serotominergic agonists) 17 171182-32-4P

RL: RCT (Reactant); SPM (Synthetic preparation); PREP (Preparation) (prepn. of triazole derivs. as serotoninergic agonists)

L7 ANSWER 2 OF 124 CAPLUS COPYRIGHT 1996 ACS
1995:969448 Document No. 124:8823 Preparation of triazole derivatives
as serotoninergic agonists. Natassa, Victor Giulio; Sternfeld,
Francinen; Street, Leslie Joseph (Nerck Sharp and Dobne tdd., UK),
PCT int. Appl. NO 9521166 A1 950810, 49 pp. DESIGNATED STATES: W:
AM, AT, AU, BB, BG, BR, BY, CA, CH, CH, CZ, DE, DK, EE, ES, FI, GB,
GE, NU, DP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, ND, MG, MN, MY,
MX, NL, NO, NZ, PL, PT, RO, RU, SO, SE, SI, SK, TJ, TT, UA, US; RV:
AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE,
IT, LU, MC, NL, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODER:
PIXXOZ. APPLICATION: MO 95-GB134 950124. PRIORITY: GB 94-2016
940202.

Title compds. [I; R = H, hydrocarbyl, heterocyclyl, etc.; R] = cycloalkyl, alkoxyalkyl, aryl(alkyl), etc.; 1 of Y,Z = M and the other = (un)substituted CH; Z1 = bond, alkylene; Z2 = 0, S, (alkyl)imino; Z3 = M, (alkyl-substituted)CH; Z4 = alkylene; p = 0 or 1; q = 1-4; prq = 2-4], agonists of 5-H11-like receptors, were prepd. Thus, (ZR)-A-tert-butoxycarboxplypyrrolidine-2-propanal was cyclocondensed with 4-{1,2,4-triazol-4-yl)phenylhydrazine (prepn. each given) and the product condensed with PhCHD to give title compd. II. I had pECSO of .gtoreq.5.0 for contraction of rabbit sanhenous wein.

cospd. II. 1 had pECSO of .gtoreq.5. saphenous vein. IT 171182-20-0P 171182-21-1P 171182-22-2P 171182-23-3P 171182-24-4P 171182-25-5P 171182-26-6P 171182-27-7P 171182-38-8P 171182-29-9P 171182-30-2P 171182-31-3P

RI: BAC (Biological activity or effector, except adverse); SPM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

17 ANSWER 3 OF 124 CAPLUS COPYRIGHT 1996 ACS
1993:93846 Document Mo. 124:688 The in vivo pharmacological profile
of a 5-HT1 receptor agenist, CP-122,788, a selective inhibitor of
neurogenic inflamation. Gupta, P.; Brown, D.; Butler, P.; Ellis,
P.; Grayson, K. L.; Land, G. C.; Macor, J. E.; Robson, S. F.;
Mythes, M. J.; Shepperson, N. B. (Departments of Discovery Biology
and Discovery Chesistry, Pfizer Central Research, Sandwich, Kent,
C113 9NJ, UK). Br. J. Pharmacol., 116(5), 2385-90 (English) 1995.
CODEN: BJPCBM. ISSN: 0007-1188.

AB The aim of the present study was to investigate the in vivo
pharmacol. profile of CP-122,788, an indole-deriv. with a
conformationally restricted M-methylpyrrolidinyl basic side chain in
the C-3 position. This C-3 substituent structurally differentiates
CP-122,788 from the S-HTID receptor agonist sumatriptan, which
possesses an N,M-dimethyl aninoethyl group. When administered prior
to elec. stimulation of the trigenimal ganglion, CP-122,288 (0.3-300)
ng kg-1. 1.v.) produced a dose-related inhibition of plasma protein,
extravasation in rat dura mater (min. ED, MED, 3 ng kg-1 1.v., P
0.05; maximal inhibition of plasma extravasation at 30 ng kg-1 1.v.,
P < 0.01). Sumatriptan produced a statlar inhibition of plasma
leakage in the dura, but at much higher dose levels (MED, 100 . mu.g
kg-1 1.v., P < 0.05). Thus, CP-122,288 is of the order of 104 fold
more potent than sumatriptan. At all doses tested, CP-122,286 dun
not inhibit plasma protein extravasation measured in extracranial
itissues such as the lower lip, eyelid, and conjunctiva. In a sep,
series of studies in the anesthetized rat, CP-122,288 (0.003-3 mu.g
kg-1 1.v.) produced no change in either heart rate or mean arterial
blood pressure, thus demonstrating that doses of CP-122,288 which
inhibit plasma protein leakage in rat dura, are devoid of
hemodymaic effects. Following a 5 min period of elec. stimulation, this
protocol permitted the evaluation of the activity of CP-122,288 on
the ongoing and established inflamatory event. CP-

Page 6

L7 ARSWER 3 OF 124 CAPLUS COPYRIGHT 1996 ACS (Continued) (CP-122,288 pharmacol, profile as selective inhibitor of neurogenic inflammation in relation to migraine treatment)

```
L7 ANSWER 4 OF 124 CAPLUS COPYRIGHT 1996 ACS (Continued)
167302-91-4P 167302-94-5P 167302-95-6P
167302-91-4P 167302-97-8P 167302-99-9P
167302-99-0P 167303-00-6P 167303-01-7P
167303-05-1P 167303-06-2P 167303-07-3P
167303-05-1P 167303-05-2P 167303-10-8P
167303-11-9P 167303-12-0P 167303-13-1-P
167303-11-9P 167303-12-0P 167303-13-1-P
167303-17-5P 167303-12-0P 167303-13-1-P
167303-17-5P 167303-12-0P 167303-13-1-P
167303-17-5P 167303-12-0P 167303-13-1-P
167303-17-5P 167303-13-5P 167303-13-0P
167303-33-5P 167303-34-6P 167303-35-0P
167303-33-5P 167303-34-6P 167303-35-0P
167303-34-5P 167303-34-6P 167303-44-8P
167303-48-5P 167303-48-0P 167303-47-1P
167303-48-2P 167303-49-3P 167303-47-1P
167303-48-2P 167303-49-3P 167303-45-9P
167303-48-2P 167303-49-3P 167303-45-9P
167303-48-2P 167303-48-9P 167303-35-9P
167303-48-2P 167303-48-9P 167303-35-9P
167303-48-2P 167303-48-9P 167303-35-9P
167303-48-2P 167303-48-9P 167303-35-9P
167303-48-2P 167303-48-3P 167303-35-9P
167303-68-2P 167303-49-3P 167303-35-9P
167303-68-2P 167303-49-3P 167303-55-9P
167303-68-2P 167303-48-3P 167303-58-9P
167303-68-2P 167303-48-9P
167303-68-2P 167303-48-9P
167303-68-2P 167303-48-9P
167303-68-2P 167303-48-9P
167303-68-2P 167303-48-9P
167303-68-2P
167303-6
```

AB The title compds., 3-(pyrrolidinylmethyl)Indoles and 3-(p)peridinylmethyl)Indoles I [R] = [2-pyrrolidinyl]methyl, 3-pyrrolidinyl, 4-piperidinyl, [3-piperidinyl]methyl; R2 = alkyl, oxoalkyl, etc.] were disclosed as selective 5-HII-like agonists useful in the treatment of mispraine, cluster headache, chronic paroxysmal heatcranta and headache assocd. with vascular disorders. A specifically claimed example compd. is 5-(3-hydroxybutyl)-3-[(R)-(1-methyl-2-pyrrolidinyl)methyl]-1-H-indole [II].

II 143322-54-9
R1: RCI (Reactant)
(prepn. of (pyrrolidinylmethyl)Indoles 5-HII-like agonists)

II 143322-57-0
R1: RCI (Reactant)
(prepn. of (pyrrolidinylmethyl)Indoles 5-HII-like agonists)

II 143322-59-0 [35325-50-9F 153525-51-0P
157303-55-0F 153705-52-9 167303-54-0P
157303-55-1 167303-55-29 167303-54-0P
157303-55-1 167303-55-29 167303-54-0P
157303-71-1P
R1: RCI (Reactant); SPM (Synthetic preparation); PREP (Preparation)
(prepn. of (pyrrolidinylmethyl)Indoles 5-HII-like agonists)

II 167302-44-59 167302-45-69 167302-45-7P
167302-47-8P 167302-45-69 167302-45-7P
167302-53-89 167302-54-7P 167302-55-8P
167302-53-89 167302-54-7P 167302-55-8P
167302-71-8P 167302-72-9P 167302-55-8P
167302-77-4P 167302-75-9P 167302-79-6P
167302-77-4P 167302-75-5P 167302-79-6P
167302-77-4P 167302-75-5P 167302-79-6P
167302-77-4P 167302-75-5P 167302-79-6P
167302-77-4P 167302-75-5P 167302-79-10-79-

L7 ANSWER 4 OF 124 CAPLUS COPYRIGHT 1995 ACS
1995:772570 Document No. 123:169499 Indole derivatives as 5-HI1-like
agonists for use in aigraine. Wythes, Martin Janes (Pfizer Ltd.,
UK; Pfizer Inc.; Pfizer Research and Development Company,
N.V./S.A.). PCT Int. Appl. WO 9424127 AI 941027, 124 pp.
DESIGNATED SIATES: W: AU, BR, CA, CN, CZ, FT, HU, JP, KR, KD, MZ,
PL, KU, US; KN: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE. (English). CODER: PIXXDZ. APPLICATION: WO 94-EP1121
940411. PRIORITY: GB 93-8360 930422; GB 93-24433 931127.

L7 ARSMER 5 OF 124 CAPLUS COPYRIGHT 1996 ACS
1995:68346 Document No. 123:313894 Z-Y-ZH compounds as potential
1,3-dipoles. Part 44. Asymmetric 1,3-dipolar cycloaddition reactions
of inines and chiral cyclic dipolarophiles. Cooper, Daniel M.;
Grigg, Ronald; Hargreaves, Simon; Kennewell, Peter; Redpath, James
(Sch. Chem., Leeds Univ., Leeds, LS2 9J), UK). Tetraheforon, 51(28),
7791-808 [English) 1995. CODEN: TETRAB. ISSN: 0040-4020.
AB Metallo-1,3-dipoles generated in situ from both arryl and aliph.
Inines of .alpha.-amino esters by the action of silver salts and
tertiary amines undergo cycloaddn. at room capp. to give
(menthyl) furo[3,4-c]pyrrolecarboxylates pyrrolopyrrolecarboxyates.
.pl.-Interaction between the dipolarophile carbonyl group and the
arryl group in the arryl inines is not required for good induction.
The stronger the base the faster the cycloaddn. with
2-t-butyl-1,1,3,1-tetranethylgundidne > DBU > MEE3. X-ray crystal
structures of representative cycloadducts established the abs.
configuration of the pyrrolidine stereocenters.

II 170027-89-1P 170027-95-9P
RL: SPN [Synthetic preparation); PREP (Preparation)
(prepn. of)

167302-80-9P 167302-81-0P 167302-82-1P 167302-83-2P 167302-84-3P 167302-92-3P

Page 7

- L7 ANSWER 6 OF 124 CAPLUS COPYRIGHT 1996 ACS
 1995:575044 Document Mo. 122:309995 Differentiating Penicillium
 species by detection of indole metabolites using a filter paper
 method. Lund, F. (Department of Biotechnology, Technical University
 of Demark, Lyngby, Den.). Lett. Appl. Microbiol., 20(4), 228-31
 [English] 1995. CODER: LAMIET. ISSM: 0266-0254.
 AB The indole secondary metabolites chaetoglobosin C, cyclopiazonic
 acid, isofuntgaclavine A and rugulovasine A and B produced by
 several Penicillium species growing on Capedy yeast autolyzate agar
 were detected directly in the culture using filter paper wetted with
 Ehrlich reagent dissolved in ethanol. The filter paper wetted with
 Ehrlich reagent dissolved in ethanol. The filter paper was placed
 on the mycelial side of an agar pluy and the metabolites were
 visualized as a violet zone on the paper within 10 min. It was
 shown that the combined characters of the violet reaction on filter
 paper and the ability to grow on creatine sucrose agar occurred in 5
 out of 16 species of Penicillium examd. A few addni. simple
 morphol, and physiol. criteria were then sufficient for
 identification of P. camemberti, P. commune, P. discolor, P.
 expansum and P. roueforti var. rouqueforti.
 II 50645-76-6, Chaetoglobosin C
 RL: ANT (Analyte); ANSI (Analytical study)
 (Differentiating Penicillium species by detection of indole
 metabolites using a filter paper method)

- 17 AMSWER 8 OF 124 CAPLUS COPYRIGHT 1996 ACS
 1995:521096 Document No. 122:310000 High-performance liquid chromatography comparison of supercritical-fluid extraction and solvent extraction of aircrobial fermentation products. Cocks, Simon; Wrigley, Stephen K.; Chicarelli-Robinson, M. Ines; Smith, Roger M. (Xenova Ltd, 240 Bath Road, Slough Berkshire, SLI 4EQ, UK). J. Chromatogr. A, 897(1 * 2), 115-22 (English) 1995. CODEN: JCCAEY.

 AB The use of supercrit. Fluids for the enter of high
- J. Chromatogr., n. 097(1 ° 2), 1837-22 [timplism], 2353.

 JCRAEY.

 The use of supercrit. fluids for the extn. of biol. active compds. from the biomass of microbial ferms. has been compared with extn. using the org. solvents methanol and dichloromethane. Compds. representing a range of structural types were selected for investigation. All the exts. obtained were examd. by reversed-phase HPLC. The extractability of metabolities using unmodified and nethanol-modified supercrit.-fluid carbon dioxide was examd. In particular detail for six microbial metabolities: chaetoglobosin A, nycolutein, luteoreticulin, 7,8-dihydro-7,8-epoxy-1-hydroxy-1-h and methanol were also extractable with methanol-modified carbon
- and methanol were also control district.

 IT 50335-03-09, Chaetoglobosin A
 RL: PUR (Purification or recovery); PREP (Preparation)
 (HPLC comparison of supercrit.-fluid vs. solvent extn. of microbial ferms. products)

17 ANIMER 7 OF 124 CAPLUS COPYRIGHT 1996 ACS
1995;549880 Document No. 122:306133 Effect of a 5-HII receptor
agonist, CP-127,288, on edema formation induced by stimulation of
the rat saphenous nerve. Kajekur, Radhika; Gupta, Paul; Shepperson,
Hicholas B.; Brain, Susan D. (Vascular Biology Research Centre,
King's College, London, Sv3 GLX, UK). Br. J. Pharmacol., 115(1),
1-2 (English) 1995. CODEN: BSPEM. ISSN: 0007-1188.

AB Neurogenic edema formation in the rat hind paw skin induced by elec.
stimulation of the saphenous nerve and neasured by extravasation of
[1251]-albunin, was inhibited by the 5-HIIB receptor agonist,
CP-93,129, and the novel tryptaine nanlog, OP-122,288 Significant
inhibition of up to 66% of control was obsd. with CP-122,288 (2
t.imes. 10-4 2 . times. 10-7 mol kg-1) and CP-93,129 (5 . times.
10-7-5 .times. 10-6 mol kg-1), with the ain. ED for CP-122,288 being
about 107 fold less than that for GP-33,129. Geam formation
induced by the intradermal administration of exogenous mediators
(substance P and histmanie) in rat dorsal skin was not inhibited by
CP-122,288 (2 . times. 10-10 mol kg-1). These results suggest that
CP-122,288 (2 . times. 10-10 mol kg-1) and that the effect may be due to a prejunctional inhibition of
neuropeptide release.

skin and that the effect may be due to a prejunctional inhibition of neuropeptide release. II 143321-74-8, CP-122288 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (neurogenic edema inhibition by 5-HII receptor agonist CP-122288)

L7 AMSWER 9 OF 124 CAPLUS COPYRIGHT 1996 ACS
1995:517652 ODCUMENT NO. 123:33479 Synthesis of Aristotelia-type
alkaloids. Part XV. Total synthesis of (+)-hobartinol. Dobler,
Markus; Anderson, James C.; Juch, Mathias; Borschberg, Hans-Juerg
(Lab. Org. Chear., Eidgenoessischen Tech. Hochschule, Zurtch,
CH-8092, Svitz.). Helv. China. Acta, 78(2), 292-300 (English) 1995.
CODEN: KCACAV. ISSN: 0018-019X.

A8 Synthetic (+)-makomakine was transformed in six steps into (+)-[17R,18R]-17,18-dihydrohobartine-17,18-diol ((+)-1) with an overall yield of 38%. This compd. was shown to be identical with natural hobartinol, a monoterprene indole alkaloid from Aristotelia australasica, originally believed to be the [175]-epimer. At the same time, the synthesis of (+)-1 delineates the hitherto unknown abs. configuration of this metabolite.

II 158812-32-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (total synthesis of hobartinol)

Page 8

- 17 AASWER 10 OF 124 CAPLUS COPYRIGHT 1996 ACS
 1995:465381 Document Mo. 122:256183 The pre- and postjunctional
 activity of CP-122/286, a conformationally restricted analog of
 sumatriptan. Beattle, David T.; Connor, Helen E. (Pharmacology II,
 Glavo Research and Development Ltd., Park Road, Ware Herts, SG12
 ODP, UK). EUr. J. Pharmacol., 276(3), 271-6 (English) 1995. CODEM:
 EJPHAZ. 1558: CO14-2999.

 AB The present study investigated the pre- and postjunctional activity
 of CP-122,288 (5-methy)-asinosul fonylmethyl-3-(M-methylpyrrolidin-2Ryl-methyl)-1H-indole), an analog of the vascular 5-H11 receptor
 agonist, sumatriptan. CP-122,288 inhibited neurogenic plasma
 protein extravasation in rat dura with a potency approx. 40 000-fold
 greater than sumatriptan (IDSO values of 0.3 pmol/kg and 13.9
 nmol/kg l.v. resp.). Rowever, CP-122,288 was only approx. 2-fold
 more potent than sumatriptan inhibiting neurogenically mediated
 contractions of the dog saphenous vein. CP-122,288 contracted the
 dog saphenous vein and basilar artery with a potency approx. 2-fold
 greater than that of sumatriptan. Both compds. possessed similar
 affinities at either human 5-H101_alpha. or 5-H10_beta. receptor s.
 It is concluded that CP-122,288 exhibits a prejunctional selectivity
 in the meninges to inhibit dural plasma protein extravasation
 independent of 5-H101_alpha. and 5-H10_beta. receptor activation.

 11 143321-74-8, CP-122288

 R.: BAC (Biological activity or effector, except adverse); B101.
 (Biological) study)
 (pre- and postjunctional activity of CP-122,286, a
 conformationally restricted analog of sumatriptan)

AMSWER 12 OF 124 CAPLUS COPYRIGHT 1996 ACS :354225 DOCUMENT MO. 122:333200 5-arylindole derivatives and their use as serotonin (5-HT)1 agonists. Macor, John Eugene (Pfizer Inc., USA). PCI Int. Appl. MO 9410)71 A1 940511, 72 pp. DESIGNATED STATES: W: AU, BR, CA, CZ, JP, KR, MO, NZ, PL, RU, US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, ML, PT, SE. (English). COURT. PIXXOZ. APPLICATION: MO 93-US9790 931019. PRIORITY: US 92-970758 921102.

- AB The title compds. I (R) = aninoalkyl; R2-R5 = H, alkyl, aryl, etc.) were disclosed. I are useful in treating migraine and other disorders; they are useful psychotherapeutics and are potent serotonin (5-HI) agonists and hearodiazepine agonists and antagonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal heaticranta and headache associd, with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. I are also useful as centrally acting antihypertensives and vasodilators. A specifically claimed example compd. is 5-cyano-1-[[3-[1-{Z-methoxyethyl}-z-pyrrolldinyl]msthyl]-3-indolyl]-1H-benrimidazole (II).

 Il 160907-04-0P 160907-05-IP 160907-06-2P
- 160907-07-32
- 160907-07-3P
 R: SPH (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 [11 143322-01-4P 151272-89-8P 151272-90-1P
 151272-90-90 151273-00-6P 151273-01-7P
 151273-05-1P 151273-06-2P 151273-07-3P
 151273-08-4P 151273-11-9P 158752-53-5P
 160906-47-91 160906-68-7P
 160906-47-8P 160906-48-9P 160906-48-7P
 160906-50-3P 160906-51-4P 160906-52-1P
 160906-83-3P 160906-51-4P 160906-82-1P
 160906-83-3P 160906-84-3P 160906-85-4P
 160906-83-3P 160906-84-3P 160906-85-6P 160906-86-5P 160906-87-6P 160906-95-6P 160905-96-7P 160906-97-8P 150907-00-6F
 - 160907-08-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)

ARSWER 11 OF 124 CAPLUS COPYRIGHT 1996 ACS

95:421524 Document No. 122:205025 Suppression by the sumatriptan analog, CP-122,288 of c-fos immunoreactivity in trigominal nucleus caudalis induced by intracisternal capsation. Cutrer, F. Michael; Schoenfeld, David; Limmroth, Volker; Panahian, Narlaan; Moskowitz, Michael A. (Narvard Med. Sch., Nassachusetts Gen. Mosp., Boston, MA. (2014, USA). Br. J. Pharmacol., 114(5), 987-92 (English) 1995.

CODEN: BJPCBN. ISSN: 0007-1188.

The effects of an 1.v. adainistered sumatriptan analog were exand. on c-fos-like immunoreactivity (c-fos-Li), a marker of neuronal activation, evoked within trigenial nucleus caudils (NtC) and other brain stem regions 2 h after intracisternal injection of the irritant, capsaticn (o.1 mo, 0.1 mM), in pentobarbitone-anesthetized Hartley guinea pigs. C-fos-Li was assessed in eighteen serial sections (50. mu.m) using a polyclonal antiserum. A weighted av., reflecting total expression within laminal, 110 of TRC was obtained from three representative levels (i.e., at -0.225 ms, -2.475 ms and -5.075 ms). Capsation caused significant labeling within laminal, 110, a region contp. axonal terminatins of small unsyclinated C-fibers, as well as within the nucleus of the solitary tract, area postress and medial reticular nucleus. A similar distribution of pos. cells was reported previously after intracisternal injection of other chem. Irritants such as autologous blood or carrageenin. Pretreatment with a conformationally restricted sumatriptan analog (with some selectivity for 5-HIB and 5-HID receptor subtypes) CP-122,288, reduced the weighted av. by approx. 50-604 (P < 0.05) in lamina 1, 110 at 100 pmol kg-1, 1.v., but did not decrease cell no. within area postrema, nucleus of the solitary tract or medical reticular nucleus. A similar pattern was reported previously following sumatriptam, dihydroergotamine or CP-93,129 administration at the anino-Et side chain of sumatriptan dramatically enhance the suppression of c-fos expression within 1RC, a finding consi

extravasation within dura matter. CP-122,288 and related analogs may serve as an important prototype for drug development in migraine and related headaches.

II 143321-74-8, CP-122288

RL: BMC (Biological activity or effector, except adverse); THU (Therapeutic use); BiOL (Biological study); USES (Uses) (suppression by sumatriptan analog, CP-122,288 of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsalcin)

```
160907-03-9P
RL: SPM (synthetic preparation); PREP (Preparation)
(prepa. of, as serotoninergic agonist)
II 151272-08-7
RL: RCI (Reactant)
(reactant for arylindole serotoninergic agonist)
II 143221-69-1 151273-09-3 160907-09-5
RL: RCI (Reactant)
(serotoninergic agonist)
```

- 1995:300051 Document No. 122:54328 Use of indole derivatives as 5-HT1
 antagonists. Macor, John Eugene (Pfizer Inc., USA). PCI Int. Appl.
 WD 9425023 H3 941110, Z2 pp. DESIGNATES IN: AU, BG, BR, CA,
 CN, C2, F1, HU, JP, KR, ND, RZ, PP, KD, RU, SX, ROH AT, BE, BF, BJ,
 CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, LE, II, LU, MC, ML,
 MR, RE, ML, PT, SE, SN, TD, TG. (English). CODEN: PIXED.
 APPLICATION: WD 94-1879 940426. PRIDRITY: US 93-5930 930427.
 AB the present invention relates to pharmaceutical coapns. conts.
 (R)-5-(acthylaminosulfonylaethyl)-3-(a-ethylpyrrolidin-2-ylaethyl)1H-indole or (R)-5-(acthylaminosulfonylaethyl)-3-(gyrolidin-2-ylaethyl)1H-indole or (R)-5-(acthylaminosulfonylaethyl)-3-(gyrolidin-2-ylaethyl)1H-indole or (R)-5-(acthylaminosulfonylaethyl)-3-(gyrolidin-2-ylaethyl)1H-indole or (R)-5-(acthylaminosulfonylaethyl)-3-(gyrolidin-2-ylaethyl)1H-indole or (R)-5-(acthylaminosulfonylaethyl)-3-(gyronidin-2-ylaethyl)1H-indole or (R)-5-(acthylaminosulfonylaethyl)-3-(gyronidin-2-ylaethyl)1H-indole or (R)-5-(acthylaminosulfonylaethyla-1)-3-(gyronidin-2-ylaethyl)1H-indole or (R)-5-(acthylaminosulfonylaethyla-1)1H-indole derivs. for treatment of disorders from deficient serotonergic neurotransmission)
 1143212-19-21-21-21
 RL: SPN (Synthetic preparation): THU (Therapeutic use): 810L

- 3321-74-BP (Asyati-78-2P RL: SPM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (Indole derivs. for treatment of disorders from deficient serotonergic neurotransmission)

AMSWER 15 OF 124 CAPLUS COPYRIGHT 1996 ACS
1:681120 Document No. 121:281120 The synthesis of
.alpha.-(3-indolylmethyl)proline-containing compounds as CCK
11gands: analogs of PD-13430B. Kendrick, David A.; Ryder, Hamish;
Semple, Graene; Sheppard, Andrew; Szelke, Michael (Res. Cent.,
Southampton univ., Southampton, SOI 78P, UK), Pept. 1992, Proc.
Eur. Pept. Symp., 22nd, Meeting Date 1992, 579-80. Editor(s):
Schneider, Conrad H.; Eberle, Alex N. ESCOM: Leiden, Meth.
(English) 1993. CODEM: SOLUMM.

- AB A report from a symposium on the stereoselective prepn. of analogs I (Adoc = 2-admantyloxycarbonyl) which have and .alpha.-(3-indoly)nethyl)proline residue in place of the .alpha.-methyl-0-tryptophan of PO 134308.

 11 158973-11-1DP, peptides contg.
 R1: RCI (Resetant): SPM (Synthetic preparation): PREP (Preparation) (asym. synthesis of .alpha.-(3-indoly)methyl)proline-contg. peptides as analogs of PO 134308).

 13 158973-12-2DP, deriver analogy. DDCD (Newsynthyl)
- - RL: SPM (Synthetic preparation); PREP (Preparation)
 (asym. synthesis of .alpha.-(3-indolylmethyl)proline-contg.
 peptides as analogs of PD 134308)

L7 AMSWER 14 OF 124 CAPLUS COPYRIGHT 1996 ACS
1995;191714 DOCUMENT NO. 122:108219 Synthesis of Aristotelia-type
alkaloids. Part XIV. total synthesis of (*)-aristolone. Dobler,
Markus; Borschberg, Hans-Juerg (Lab. Org. Chem., Eldgenoessischen
Technischen Hochschule, Zurich, CH-8092, Switz.). Tetrahedron:
Asymmetry, 51(0), 2025-32 (English) 1994. COBER: IASYE3. ISSN:
0957-4166. OTHER SOURCES: CASREACT 122:106219.

- The first total synthesis of the highly functionalized monoterpenoid indole alkaloid (*)-aristolone (I) is described. This investigation uncovered the hitherto unknown relative and abs. configuration of this rare metabolite which had been isolated before by others in ppo-amis. From Aristotelia australasica. Dehydration of synthetic I led to a readily separable anit. of the two alkaloids 1,1,2-didehydro-1-oxonakomakine and IT 159979-26-7P
 - RL: SPN (Synthetic preparation); PREP (Preparation) (total synthesis of aristolone)

- L7 AKSWER 16 OF 124 CAPLUS COPYRIGHT 1996 ACS
 1994:680497 Document No. 121:280497 Use of 2,5-Dimethylpyrrole as an
 Anino-Protecting Group in an Efficient Synthesis of
 5-Aaino-3-[(H-methyl-pyrrolidin-2(R)-yl)aethyl]indole. Macor, John
 E.; Chenard, Bert L.; Post, Ronald J. (Department of Medicinal
 Chemistry, Pfizer Inc., Groton, CT, 06340, USA). J. Org. Chem.,
 59(24), 7496-8 (English) 1994. CODEN: JOCEAN: ISSN: 0022-1263.
 OTHER SOURCES: CASREACT 121:280497; CLACS-IMAGE; CLACS.
 AB 5-Aaino-3-(K-methylpyrrolidin-2R-ylmethyl)indole was synthesized in
 an overall of 39% in four steps on a large scale. Crucial to the
 success of this sequence was the use of a 2,5-dimethylpyrrole as the
 protecting group for the 5-aminoindole functionality. This
 protecting group was stable to (unreactive toward) ethylmagnesium
 bromide, a hindered acid chloride (CEZ-proline acid chloride), and
 lithium aluminum hydride, but eastly removed in high yield using
 unique conditions (hydroxylamine hydrochloride/triethylamine/propano
 l/vater/.DELTA.).
 I 151273-49-39 158752-53-59
 RL: RCI (Reactancl; SPR (Synthetic preparation); PREP (Preparation)
 (use of dimethylpyrrole as an anino-protecting group in an
 efficient synthesis of maino[(methylpyrrolidinyl)methyl]indole)
 RL: SPR (Synthetic preparation); PREP (Preparation)
 (use of dimethylpyrrole as an anino-protecting group in an
 efficient synthesis of amino[(methylpyrrolidinyl)methyl]indole)

L7 AMSWER 17 OF 124 CAPLUS COPYRIGHT 1996 ACS
1994-631280 Document No. 121:231280 Non-decarboxylative 1,3-dipolar
cycloadditions of Imines Of alpha.—anino acids as a route to
proline derivatives. Aly, Moustafa F.; Younes, Mansour I.;
Metwally, Saoud A. M. (Fac. Sci., Assiut Univ., Qena, Egypt).
1etrahedron, 50(10), 3159-68 (Egnish) 1994. CODER: TETRAB. ISSM:
0040-4020. OTHER SOURCES: CASREACT 121:231280.

AB The 1,3-dipolar cycloaddn. reaction of alanine with salicylaldehyde and M-substituted maleinides 1 (R = Me, Ph) gave stereospecific cycloadducts ii. The 1,3-dipolar cycloaddn. reaction of .alpha.-maino acids with anyl aldehydes in the presence of di-Me fumarate gave isomeric cycloadducts III (Ar = 2-hydroxyphenyl, R] = Me, N, CHZCHMC2, CHZCHZSMe, CHZPh, indol-3-ylmethyl; Ar Ph, 2-methoxyphenyl, 2,4-dimethoxyphenyl, R] = Me) and IV (Ar and R] = same). The relatively low yield in the case of di-Me fumarate is presumably due to the steric interaction between the dipolarophile and the substituents at both ends of the dipole.

Il 158134-75-99 158249-37-7P
RL: SPN (Synthetic preparation); PREP (Preparation)

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)

ANSWER 19 OF 124 CAPLUS COPYRIGHT 1996 ACS ANNEW 19 OF 124 CAPLUS COPYRIGHT 1996 ACS
553524 Document No. 121:153524 A novel mycotoxin: the
chaetoglobosin N from infested maize by Phomopsis leptostromiformis.
11. Structure elucidation by 1H and 13C MMR. Convert, 0.; Jellai,
A; Correla, 1.; Dardoize, F.; Menguy, L.; Cherton, J. C. (Lab.
Chim. Organ. Struct., Univ. Pierre et Marie Curie, Paris, 75005,
Fr.). Analusis, 22(4), 217-21 (English) 1994. CODEN: AMLSCY.
ISSN: 0365-4877.

ISSM: 0365-4877.

From culture on malze of the strain MRC 2654 of P.
leptostroniformis, two fungal metabolites, unusual to this fungus, nave been isolated in the methanolic ext. IH and I3C MMR spectra allowed the establishment for these noils. some partial structures contg. an indole unit and several condensed cycles. On the basis of these MMR results, the compd. F = 185.degree. Is identified to the term N of the chaetoglobosin series and the more polar compd., F = 205.degree., named chaetoglobosin N, appears to be a new term in this series.

and this series.

II 119212-28-1, Chaetoglobosin M
Rt. Blol (Biological study)

(from Phomopsis leptostromiformis-infected corn)

II 169800-59-5, Chaetoglobosin M
Rt. Blol (Biological study)

(from Phomopsis leptostromiformis-infected corn, structure of)

08/466,644 Page 10

17 AMSWER 18 OF 124 CAPLUS COPYRIGHT 1996 ACS
1999:574790 Document No. 121:174790 Antifungal substances produced by Chaetomium globosum. Amestya, Yoshimiki; Kondo, Akihiro; Hirano, Kazuya; Hirukawa, Toshihumi; Kato, Tadahiro (Fac. Nortic., Chiba Univ., Matsudo, 271, Japan). Chiba Omigaka Enegisyakub Gakujutsu Hokoku, 48, 13-18 (Japanese) 1994. CDDEM: CDEGAF. ISSN: 0009-3227. AB Antifungal substances were extd. from culture filtrate of the most antagonistic isolate identified as chaetomium globosum. Two active substances were obtained by using silica gel column chromatog. and high performance liq. chromatog. By analyzing with mass spectrometer (EINS, NR-NS), IH-MRN and 13C-MRN, the major substance was identified as Chaetoglobosin A, one of the toxic metabolites produced by C. globosum and C. chochilodes. Another substance was assumed to have saillar structure with Chaetoglobosin A. The major substance completely inhibited the spore germination of V. dahline at 32 .mu.g/ml. It was also active against V. albo-atrum and Rhizoctonia solani, but not against Fusarium oxysporum, F. solani and Pythium aphanidermatum.

11 S0135-03-0, Chaetoglobosin A
RI: BAC (Biological activity or effector, except adverse); BIOL (Biological study) (from Chaetomium globosum, antifungal activity of, against Verticillium and Rhizoctonia)

ANSWER 20 OF 124 CAPLUS COPYRIGHT 1996 ACS ARSWER 20 OF 124 CAPLUS COPYRIGHT 1996 ACS: 1501581 Document No. 121:101581 Unexpected production of chaetoglobosins from maize incubated by Phomopsis leptostroniformis.

I. Isolation and optimization of the production in liquid media by LC monitoring. Cherton, J. C.; Jellal, A.; Lhommet, G.; Louteller, C.; Dardoize, F.; Lacoste, L.; Subileau, C. (Dep. Chim., Univ. Versailles Saint-Quentin Yvelines, Versailles, 78001, Fr.). Analusis, 22(4), 210-16 (English) 1994. CODEN: ANLSCY. ISSN: 0365-4877.

Analusis, 22(4), 210-16 (English) 1994. CODEM: AMLSCY. ISSN: 0365-4877.

AB Attempts to obtain the toxin phomopsin A, usually isolated from P. leptostromiformis fungus, failed when infesting malze with strain MRC 2654 of this fungus. However, taking into account the acute toxicity for rats of the crude methanol ext., mycotoxins less polar than phomopsins were searched for by checking other sepn. procedures. Preparative silica TLC entailed the localization of the toxicity in the fraction sol. in iso-Prether. Preparative HPLC on silica allowed the purifn. of 2 toxins shown to belong to the chaetoglobosin series. A LC method for direct monitoring of the prodn. of these toxins in liq. acida resulted in a first optimization of the culture conditions. It appeared that the yields of these toxins can be increased approx. 4-fold by reducing the culture of P. leptostromiformis in darkness from 28 to 10 days.


II ISOBM (Formation, nonpreparative)

{formation of, by Phomopsis leptostromiformis, prodn. optimization and sepn. of, in liq. media by liq. chromatog. monitoring in relation to)

II 11212-29-1, Chaetoglobosin M

RL: BlU, (Biological study)
{prodn. optimization and sepn. of, in liq. media by liq. chromatog. monitoring)

=> d que 14 stat STR



REP G20=(0-2) 11-12 11-15

NODE ATTRIBUTES:

HODE VILKIDOLES.			
IS	M2	ΑT	10
IS	R	ΑT	1
IS	R	ΑT	2
IS	R	ΑT	3
IS	R	ΑT	4
IS	R	ΑT	5
IS	R	ΑT	6
IS	R	ΑT	7
IS	R	ΑT	8
IS	С	ΑT	10
IS	R	ΑT	11
IS	R	ΑT	12
IS	R	ΑT	13
IS	R	ΑT	14
IS	R	ΑT	15
IS	R	ΑT	16
DEFAULT MLEVEL IS ATOM			
DEFAULT ECLEVEL IS LIMITED			
	IS	IS M2 IS R	IS M2 AT IS R AT

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

756 SEA FILE=REGISTRY SSS FUL L3

100.0% PROCESSED 13566 ITERATIONS

SEARCH TIME: 00.00.42

756 ANSWERS

```
L4 AMSVER 1 OF 756 REGISTRY COPYRIGHT 1996 ACS
RM 171550-16-6 REGISTRY
CM INDEX NAME NOT YET ASSIGNED
FS SITEROSEARCH
MF C16 H19 M5 . x H2 O4 S
RC CA
LC SIM FILES: CAPLUS
CM 1

CRM 171550-15-5
CM5 C16 H19 M5
CCS 1: S
```

Absolute stereochemistry.

CM S

CRN 7664-93-9 CMF H2 04 \$

HO- S- OF

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

CM 2

CRM 144-62-7 CMF C2 H2 O4

0 0 || 1| HO-C-C-OH

> 1 REFERENCES IN FILE CAPREVIEWS 1 REFERENCES IN FILE CA (1967 TO DATE) 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 124:8823

```
L4 ARSWER 5 OF 756 REGISIRY COPYRIGHT 1996 ACS
RM 171182-32-4 REGISIRY
CM 1H-Indole, 3-(2-pyrrolidinylmethyl)-5-(4H-1,2,4-trlazol-4-yl)-, (R)-
(9CI) (CA INDEX MAME)
FS SIEREOSEARCH
NF CIS HIT MS
SR CA
LC STM Files: CA, CAPLUS, CAPREVIEWS
CDS 1:R
Absolute stereochemistry.
```

1 REFERENCES IN FILE CAPREVIEWS 1 REFERENCES IN FILE CA (1967 TO DATE) 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 124:8823

```
L4 ANSWER 14 OF 756 REGISTRY COPYRIGHT 1996 ACS
RM 171182-23-3 REGISTRY
CM Acetande, M-[4-[2-[5-(4H-1,2,4-triazol-4-y1)-1H-1ndol-3-y1]nethyl]-1-pyrrolidinyl]nethyl]phenyl]-, (R)-, ethanedioate [1:1)
[9C:1] (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H26 M5 0 . C2 H2 O4
SR CA
LC STM Files: CA, CAPLUS, CAPREVIEWS
CM 1
CRM 171182-22-2
CMF C24 H26 M5 0
CDES 1:R
Absolute stereochemistry.
```

CH 2

CRN 144-62-7 CMF C2 H2 O4

0 0 II II но-2-2-он

> 1 REFERENCES IN FILE CAPREVIEWS 1 REFERENCES IN FILE CA (1967 TO DATE) 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 124:8823

AMSWER 18 OF 756 REGISTRY COPYRIGHT 1996 ACS 170027-95-9 REGISTRY
Pyrrolo[3,4-c]pyrrole-1-carboxyllc acid, 5-acetyloctahydro-1-(1H-indol-3-ylacthyl)-6-(1-acthylethoxy)-3-(2-naphthalenyl)-4-oxo-, metnyl ester, [15-(1.alpha.,3.alpha.,3a.beta.,6.beta.,6a.beta.]]SITERESEARCH
C32 H33 H3 OS
CA
SITM Files: CA, CAPLUS

Absolute stereochemistry.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:313894

AMSWER 44 OF 756 REGISTRY COPYRIGHT 1996 ACS
167303-39-1 REGISTRY
4-Penten-2-ol, 2-methyl-5-[3-{(1-methyl-2-pyrrolidinyl)methyl]-lhindol-5-yl]-, (R) (9CI) (CA INDEX MAME)
SIERCOSCARCH
CZO NZO NZ O CA
SIM FILES: CA, CAPLUS
1:R

Absolute stereochemistry.
Double bond geometry unknown.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:169499

08/466,644

L4 AASWER 28 OF 756 REGISIRY COPYRIGHT 1996 ACS
RM 167303-55-2 REGISIRY
CN 1-Pyrrollidinecarboxylic acid, 2-[[5-[2-(1-hydroxycyclopentyl)ethyl]1H-indol-3-yl]aethyl]-, phenylaethyl ester, (R)- (9CI) (CA INDEX
MAME)
FS SIERCOSEARCH
MF C28 H34 NZ 03
SR CA
CC SIM Files: CA, CAPLUS
DES 1:R

Page 3

Absolute stereochemistry.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:169499

AMSYER 48 OF 756 REGISTRY COPYRIGHT 1996 ACS
167303-35-7 REGISTRY
4-Penten-Z-ol, 5-[3-[(1-methyl-2-pyrrolidinyl)methyl]-1H-indol-5-yl](9CI) (CA INDEX MAME)
3D CONCORD
C19 H26 NZ 0

(9CI) (CA INDEX MARE)
FS 3D CONCORD
MF C19 H26 M2 0
SR CA
LC STM Files: CA, CAPLUS

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:169499

L4 ARSWER 54 OF 756 REGISTRY COPYRIGHT 1996 ACS
RM 16/303-29-9 REGISTRY
CH 1-Penten-3-ol, 3-ethyl-1-[3-[(1-methyl-2-pyrrolldinyl)methyl]-]Hindol-5-y]-, (R)- (9CI) (CA INDEX NAME)
FS STERCOLEARCH
F C21 M30 NZ 0
SR CA
CC STR F1les: CA, CAPLUS
DES 1:R

Absolute stereochemistry.

Double bond geometry unknown.

1 REFERENCES IN FILE CA (1967 TO DATE) 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:169499

L4 RN CN

AMSWER 73 OF 756 REGISTRY COPYRIGHT 1996 ACS
167303-09-5 REGISTRY
Acctamide, N-[2-{2-[[5-{2-{1-hydroxycyclopentyl}ethyl]-]H-indol-3-yl]aethyl]--pyrrolidinyl]ethyl]-, {R}- (9CI) (CA IMDEX MAME)
SIEREOSEARCH
C24 H35 N3 02
CA
SIM Files: CA, CAPLUS

y1]m FS STER MF C24 SR CA LC STN DES 1:R

Absolute stereochemistry

1 REFERENCES IN FILE CA (1967 TO DATE) 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:169499

08/466,644

AMSWER 68 OF 756 REGISTRY COPYRIGHT 1996 ACS
167303-14-2 REGISTRY
1H-Indole-5-propanol, .alpha.-cyclopentyl-3-{Z-pyrrolidinylmethyl}3D CONCORD
C21 H30 NZ 0
CA
STM Files: CA, CAPLUS

Page 4

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:169499

L4 ARSWER 89 OF 756 REGISTRY COPYRIGHT 1996 ACS
RM 167302-93-4 REGISTRY
CN 1-Pyrrolidinepropananide, Z-[[5-(3-hydroxy-3-methylbutyl)-1H-1mdol-3-yl]methyl]-H,_alpha.-dimethyl-, [R-(R*,R*)]- [9CI) (CA INDEX NAME)
F3 STERCOSEARCH
F CZ3 835 A3 02
SR CA
CA
CS TM Files: CA, CAPLUS
DES 1:R2:R*,R*

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:169499

L4 ARSWER 101 OF 756 REGISTRY COPYRIGHT 1996 ACS
RM 16/302-74-1 REGISTRY
CM 1-Pyrrolidineacetamide, 2-[[5-[2-(1-hydroxycyclopenty1]ethy1]-]Hind01-3-y1]methy1]-M-methy1-, (R)- (9CI) (CA INDEX MAME)
FS STERCOSEARCH
F C23 M33 M3 O2
SR CA
CA
LC SIM Files: CA, CAPLUS
DES 1:R

Absolute stereochemistry.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:169499

AMSWER 330 OF 756 REGISIRY COPYRIGHT 1996 ACS 152305-25-4 REGISIRY 1H-Indole-5-propanol, .beta.-amino-3-[(1-methyl-2-pyrrolidinyl)]achyl]-, [R-{R*,R*}]- (9CI) (CA INDEX MAME) SIEREOSEARCH

pyrrolidinyl]methyl]-, :
FS STEREOSEARCH
MF C17 E25 M3 O
SR CA
LC STM Files: CA, CAPLUS
DES 1:R2:R*,R*

Absolute stereochemistry.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 120:106761

08/466,644

Page 5

L4 AMSWER 254 OF 756 REGISTRY COPYRIGHT 1996 ACS
RM 153435-54-2 REGISTRY
CN 1-Pyrrolidinecarboxylic acid, 2-{[5-[3-{(dimethylamino)carbonyl]phen yl}-1h-indoi-3-yl]methyl}-, phenylmethyl ester, (R)- {9Cl} (CA INDEX MAME)
FS SIEREOSEARCH
NF C30 N31 N3 O3
SR CA
CC SIM Files: CA, CAPLUS
DES 1:R

Absolute stereochemistry.

3 REFERENCES IN FILE CA (1967 TO GATE) 3 REFERENCES IN FILE CAPLUS (1967 TO GATE)

REFERENCE 1: 120:217271

ANSWER 458 OF 756 REGISTRY COPYRIGHT 1996 ACS
143322-03-6 REGISTRY
Methanesulfonanide, N-[3-{[1-methyl-2-pyrrolldinyl]methyl]-1H-Indol-5-yl]-, (R. |901) (CA INDEX NAME)
STEREOSEARCH
C15 N21 N3 02 S
CA
SIN Files: CA, CAPLUS

Absolute stereochemistry.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 117:171215

L4 AMSWER 529 OF 756 REGISTRY COPYRIGHT 1996 ACS
RM 111141-39-0 REGISTRY
CN Indole, 3-[(1-methyl-2-piperidyl)methyl]-, hydrochloride (6C1) (CA
IMDEX MAME)
MF C15 R20 NZ . C1 H
SR CADLD
LC SIM Files: BEILSTEIN*, CAOLD
[*File contains numerically searchable property data)
CRM [10183Z-07-9]

● RC1

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

ANSWER 600 OF 756 REGISTRY COPYRIGHT 1996 ACS
70265-28-0 REGISTRY
6,7-1Sequinolinediol, 1,2,3,4-tetrahydro-1-[(5-hydroxy-1H-1ndol-3-y1)aethyl]- (9CI) (CA INDEX MAME)
30 CDMCPDB
C18 H18 M2 03

08/466,644

L4 AMSWER 578 OF 756 REGISTRY COPYRIGHT 1996 ACS
RM 80375-19-5 REGISTRY
CN [13]Cytochalasa-6(12),13,17,21-tetraene-1,20,23-trione,
19-6acetyloxy)-7-4ydroxy-10-(1H-indo)-3-yi)-16,18-dimethyl-,
(75,38;,165,176,19R,21E)- (9CI) (CA IMDEX MAME)
OHER CAA INDEX MAMES:
CN 1H-Cyclotridec(d)Isoindole, [13]cytochalasa-6(12),13,17,21-tetraene1,20,23-trione deriv.
OHER MAMES:
CN 19-0-Accetylchaetoglobosin D
CN Chaetoglobosin D 19-acetate
FS SIERCOSEARCH
MF C34 H36 M2 06
LC SIM Files: CA, CAPLUS, MAPRALERI
DES 4:75,13E,165,17E,19R,21E.(13)CYTOCHALASAM

Page 6

Absolute stereochemistry.

Oouble bond geometry as described by E or Z.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 96:31294

AMSWER 618 OF 756 REGISTRY COPYRIGHT 1996 ACS
61326-32-1 REGISTRY
1H-PyrIdo[3,4-b] Indo]-6-ol, 2,3,4,9-tetrahydro-1-{1H-indo]-3-ylnethy]-{9CI} (CA INDEX MAME)
3D CONCORD
CCO H19 M3 O
CCM
STM Files: BEILSTEIM*, CA, CAPLUS, IFICOB, IFIPAT, IFIUDB, USPATFUL
(*File contains numerically searchable property data)

FS MF C1 LC

2 REFERENCES IN FILE CA (1967 TO DATE) 2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 90:38902

REFERENCE 2: 86:29789

Page 7

L4 ARSWER 723 OF 756 REGISTRY COPYRIGHT 1996 ACS
RM 16957-07-8 REGISTRY
CR Isoquinoline, 1,2,3,4-tetrahydro-3-{indol-3-ylmethyl}-6-methoxy-2-methyl-{6C1} (CA INDEX KAME)
FS 3D CDKCORD
MF C20 NEZ RZ 0
CS 51M Files: BEILSIEIM*, CA, CAPLUS
{*File contains numerically searchable property data}

2 REFERENCES IN FILE CA (1967 TO DATE) 2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 2: 69:67588

L4 AMSWER 756 OF 756 REGISTRY COPYRIGHT 1996 ACS
RM 5275-03-6 REGISTRY
CM Pyridinium, 2-(18-indol-3-ylmethyl)-1-methyl-, iodide (9CI) (CA
INDEX MAME)
OTHER CA INDEX MAMES:
CM 2-(Indol-3-ylmethyl)-1-methylpyridinium iodide (6CI, 7CI)
CM Pyridinium, 2-(indol-3-ylmethyl)-1-methyl-, iodide (8CI)
MF C15 H15 N2 . I
LC SIM Files: BEILSTEIM*, CAOLD, TOXLIT
(*File contains numerically searchable property data)
CRM (17795-28-7)

2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ARSWER 755 OF 756 REGISTRY COPYRIGHT 1996 ACS
RM 5275-05-8 REGISTRY
CN 1H-Indole, 3-(2-piperidinylmethyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indole, 3-(2-piperidylmethyl)- (6CI, 7CI, 8CI)
OTHER NAMES: OTHER MAMES:

CM 3-(2-Piperidylmethyl)indole
FS 3D COMCORD

NF C14 RIB NZ
C1 COM

C5 TN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CJACS, RTECS*

(*File contains numerically searchable property data)

5 REFERENCES IN FILE CA (1967 TO DATE) 5 REFERENCES IN FILE CAPLUS (1967 TO DATE) 5 REFERENCES IN FILE CAOLO (PRIOR TO 1967)

REFERENCE 1: 317:171215 REFERENCE 2: 117:26178 REFERENCE 3: 98:160993 REFERENCE 4: 91:140663 REFERENCE 5: 77:126393

=> fil caold FILE 'CAOLD' ENTERED AT 18:41:53 ON 07 JAN 96 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 1996 AMERIÇAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1957-1966 FILE LAST UPDATED: 30 OCT 91 (910803/ED)

To help control your online searching costs, consider using the HCAOLD File when conducting SmartSELECT searches with large numbers of terms.

=> s 14

L5 20 L4

=> d 1-20

L5 ANSWER 1 OF 20 COPYRIGHT 1996 ACS AN CA65:18640c IT 10438-16-1 10438-37-2 10438-19-4 20165-95-1

LS ARSWER 2 OF 20 COPYRIGHT 1996 ACS
AR CA65:16973a
OI P
17 7670-46-4 7695-23-0 17971-17-4 99813-09-9

L5 ANSWER 3 OF 20 COPYRIGHT 1996 ACS AN CA65:13714a DI P 11 7546-61-4 7546-63-6 16060-17-6

L5 ARSWER 4 OF 20 COPYRIGHT 1996 ACS AM CA65:13713h DT P 17 7546-58-9 7546-59-0 7551-14-6 101811-43-2

Page 10

LS AMSWER 5 OF 20 COPYRIGHT 1996 ACS AM CA65:13713f OT P II 7551-08-8 14128-30-4 LS ANSWER 6 OF 20 COPYRIGHT 1996 ACS AN CA65:13713e DT P IT 7546-60-3 7551-09-9

L5 AMSWER 7 OF 20 COPYRIGHT 1996 ACS AM CAC4:17539b 1T 5697-98-3 5697-99-4 LS ANSWER 8 0F 20 COPYRIGHT 1996 ACS
AN CAG4:141619
1T 3515-49-9 S275-03-6 5275-04-7 5275-05-8 5275-06-9
5275-42-3 5275-88-1 5323-45-5 5353-45-7 5580-44-9
5968-98-9 30701-36-1 90325-65-8 90325-67-0 107628-26-2

Page 11

LS ARSWER 9 OF ZO COPYRIGHT 1996 ACS AM CAG1:132784 II 455-64-0 55818-08-1 56966-37-1 93726-90-0 94759-97-4 94801-80-6 95133-76-9 96977-34-7 97115-04-3

L5 AMSWER 10 OF 20 COPYRIGHT 1996 ACS AM CA57:1657a DT P IT 5275-05-8 58383-32-7

L5 ANSWER 11 0F 20 COPYRIGHT 1996 ACS AM CAS5:11442f DI P 117 5275-05-8 92647-88-6 100168-19-2 102461-04-1

L5 ANSWER 12 OF 20 COPYRIGHT 1996 ACS AM CAS3:13146f 1T 110421-90-4

08/466,644 Page 12

L5 ANSWER 13 OF 20 COPYRIGHT 1996 ACS AN CAS3:13146d IT 103268-60-6 132687-26-4 LS ANSWER 14 OF 20 COPYRIGHT 1996 ACS AM CAS3:6226f IT 3515-49-9 5275-05-8 21182-09-2 57637-79-3 110179-40-3 110179-78-7

L5 AMSWER 15 OF 20 COPYRIGHT 1996 ACS AM CA53:3146e IT 102173-76-Z L5 AKSWER 16 OF 20 COPYRIGHT 1996 ACS AM CA52:5406f IT 1111141-39-0 08/466,644 Page 13

L5 ARSWER 17 0F 20 COPYRIGHT 1996 ACS AM CAS2:5405e 11 5275-05-8 92292-23-4 110179-40-3 125614-62-2

L5 AMSWER 18 OF 20 COPYRIGHT 1996 ACS AM CA51:6702h DT P 1T 5275-03-6 5580-44-9

LS AMSMER 19 OF 20 COPYRIGHT 1996 ACS AM CAS1:6702g OI P IT 100880-55-5

LS ANSWER 20 OF 20 COPYRIGHT 1996 ACS AN CAS1:6702f OT P IT 102025-60-5 111529-88-5

Page 14

=> fil caplus
FILE 'CAPLUS' ENTERED AT 18:42:36 ON 07 JAN 96
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1996 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1967 - 7 Jan 1996 VOL 124 ISS 2 FILE LAST UPDATED: 6 Jan 1996 (960106/ED)

To help control your online searching costs, consider using the HCAplus file when using the FSEARCH command or when conducting SmartSELECT searches with large numbers of terms.

=> s 14

L6 180 L4

=> d 1-40 cbib abs hitrn

08/466,644 Page 15

L6 ARSWER 1 OF 180 CAPLUS COPYRIGHT 1996 ACS
1995;887946 Preparation of [[triazo]y]lindo]y]aethylpyrrolidines as
5-H11-like agonists. Matassa, Yittor Giulio; Sternfeld, Francine;
Street, Leslie Joseph (Merck Sharp and Dohme Ltd., UK). PCI Int.
Appl. NO 9521167 Al 950810, 22 pp. DESIGNATED STATES: W: AM, AT,
AM, BB, BG, BR, BY, CA, CH, CH, C, CP, DE, DK, EE, ES, FI, CB, GE, HU,
JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LY, ND, NG, NM, NM, NX, NL,
NO, NZ, PL, PI, RO, RU, SD, SS, IS, KS, TJ, TT, LM, LUS KS: AT, BE,
BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU,
NC, NL, NR, KE, NL, PI, SE, SM, TD, TG. (English). CODEN: PIXXO2.
APPLICATION: NO 95-GB13S 950124. PRIORITY: GB 94-2011 940202.
AB litle compds. (1: R = H, C1-6 alkyl), were prepd. Thus,
4-[1,2,4-triazo]-4-[y]phenylhydrazine and (25)-M-tertbutoxycarbonyl-3-(pyrolidin-2-y)lpropanal were stirred in 4% aq.
12504 at rooms temp.-reflux to give 34% I (R = H), isolated as the
oxalate. I showed pECSO. gtoreq.5.0 in a test of their ability to
mediate contraction of the saphenous vein of rabits.

17 RN LIST MAY NOT BE COMPLETE: 154594-16-8 171550-13-3
171550-14-4 171550-15-5 171550-16-6

L6 ANSWER Z OF 180 CAPLUS COPYRIGHT 1996 ACS (Continued) (prepn. of triazole derivs. as serotoninergic agonists) IT 171182-32-4P

RI: RCI (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. of triazole derivs. as serotoninergic agonists)

L6 ANSWER 2 OF 180 CAPLUS COPYRIGHT 1996 ACS
1995:95948 Document No. 124:8823 Preparation of triazole derivatives
as serotoninergic agonists. Natassa, Victor Giulio; Sternfeld,
Francine; Street, Leslie Joseph (Merck Sharp and Dobnae tod., UK),
PCT Int. Appl. NO 9521168 A1 950810, 49 pp. DESIGNATED STATES: W:
AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FT, GB,
GE, RU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, NO, MG, MN, MV,
MX, NL, NO, NZ, PL, PT, RO, RU, SO, SE, SI, SK, TJ, TT, UA, US; RN:
AT, BE, BF, BJ, CF, GG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE,
IT, LU, MC, ML, NR, NE, NL, PT, SE, SN, TD, TG. (English). CODER:
PIXXD2. APPLICATION: MO 95-G8134 950124. PRIORITY: GB 94-2016
940202. 940202.

Title coapds. [I; R = H, hydrocarbyl, heterocyclyl, etc.; RI = cycloalkyl, alkoxyalkyl, aryl(alkyl), etc.; l of Y.Z = H and the other = (un)substituted (CH; ZI = bond, alkylene; ZZ = 0, S, {alkyl}taino; Z3 = N, {alkyl-substituted}CH; Z4 = alkylene; p = 0 or l; q = 1-4; prq = 2-4], agonists of 5-HII-like receptors, were prepd. Thus, {ZP}---ter-butoxycarbonylpyrrolidine-Z-propanal was cyclocondensed with 4-{1,2,4-triazol-4-yl}phenylhydrazine (prepn. each given) and the product condensed with PhChD to give title compd. II. I had pECSO of .gtoreq.5.0 for contraction of rabbit saphenous vein. saphenous vein.

IT 171182-20-0P 171182-21-1P 171182-22-2P 171182-23-3P 171182-24-4P 171182-25-5P 171182-26-6P 171182-27-7P 171182-28-8P 171182-29-9P 171182-30-2P 171182-31-3P RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

ANSWER 3 OF 180 CAPLUS COPYRIGHT 1996 ACS

16 AKSWER 3 OF 180 CAPLUS COPYRIGHS 1996 ACS
1995:933386 Document Mo. 124:688 The in vivo pharmacological profile
of a S-HII receptor agonist, CP-122,288, a selective inhibitor of
neurogenic inflammation. Gupta, P.; Brown, D.; Butler, P.; Ellis,
P.; Grayson, K. L.; Land, G. C.; Macor, J. E.; Robson, S. F.;
Wythes, M. J.; Shepperson, M. B. (Departments of Discovery Biology
and Oiscovery Chemistry, Prizer Central Research, Sandwich, Kent,
CT13 9MJ, UK). Br. J. Pharmacol., 118(5), 2385-90 (English) 1995.
CODEM: BAPCBM. ISSM: 0007-1188.

AB The aim of the present study was to investigate the in vivo
pharmacol. profile of CP-122,288, an indole-deriv. with a
conformationally restricted M-methylpyrrolidinyl basic side chain in
the C-3 position. This C-3 substituent structurally differentiates
CP-122,288 from the S-HIID receptor agonist sumarriptan, which
possesses an M,A-dimethylaminochyl group. When administered prior
to elec. stimulation of the trigeninal ganglion, CP-122,288 (0.3-300
ng kg-1, 1.v.) produced a dose-related inhibition of plasma protein,
extravasation in rat dura mater (min. ED, MED, 3 ng kg-11.v., P <
- 0.05; maximal inhibition of plasma extravasation at 30 ng kg-11.v.,
P < 0.01). Sumatriptan produced a similar inhibition of plasma
leakage in the dura, but at much higher dose levels (MED, 100 .au.g
kg-11.v.) produced not shape a story of the order of 104 fold
more potent than sumatriptan. At all doses tested, CP-122,288 did
not inhibit plasma protein extravasation measured in extraramala
tissues such as the lower 1p, eyelid, and conjunctiva. In a sep,
series of studies in the anesthetized rat, CP-122,288 (0.003-3 .mu,
kg-1.v.) produced no change in rat dura, are devoid of
henodynanic effects. Following a 5 min period of elec. stimulation
of the trigeninal agnilion, a 20 min period of sustained
neurogenically-driven plasma extravasation neature in the basence
of elec. stimulation, was intilated. By administration of the
compd. 5 min after completing the phase of elec. stimulation, this
protocol permit

#3321-74-8, CP-122288
RI: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

Page 16

L6 AMSVER 3 OF 180 CAPLUS COPYRIGHT 1996 ACS (Continued)
(CP-122,288 pharmacol. profile as selective inhibitor of
neurogenic inflammation in relation to migraine treatment)

```
ANSWER 4 OF 180 CAPLUS COPYRIGHT 1996 ACS (Continued)
167303-02-87 167303-03-9P 167303-04-0P
167303-05-1P 167303-06-2P 167303-07-3P
167303-08-4P 167303-06-2P 167303-10-8P
167303-18-1P 167303-12-07 167303-13-1P
167303-14-2P 167303-15-3P 167303-16-4P
167303-14-2P 167303-15-3P 167303-16-4P
167303-12-9P 167303-12-9P 167303-23-3P
167303-20-0P 167303-21-1P 167303-23-3P
167303-20-0P 167303-28-8P 167303-29-9P
167303-32-4P 167303-28-8P 167303-32-4P
167303-32-8P 167303-31-3P 167303-32-4P
167303-34-8P 167303-31-3P 167303-31-0P
167303-34-9P 167303-31-3P 167303-31-0P
167303-34-9P 167303-41-5P
167303-42-6P 167303-49-3P 167303-41-5P
167303-42-6P 167303-49-3P 167303-31-0P
167303-57-3P
167
```

L6 AMSWER 4 OF 180 CAPLUS COPYRIGHT 1996 ACS
1995:772570 Document No. 123:169499 Indole derivatives as 5-H11-like
agonists for use in algraine. Wythes, Martin James (Pfizer Ltd.,
UK; Pfizer Inc.; Pfizer Research and Development Company,
M.V./S.A.). PCT Int. Appl. NO 9424127 A1 941027, 124 pp.
DESIGNAMED SIATES: W: AU, BR, CA, CH, CZ, FI, HU, JP, KR, NO, NZ,
PL, RU, US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE. (English). CODER: PIXICE2. APPLICATION: NO 94-EP1121
940411. PRIORITY: GB 93-8350 930422; GB 93-24433 931127.

A8 The title compds., 3-(pyrrolidinylmethyl)indoles and 3-(piperidinylmethyl)indoles I [R] = [2-pyrrolidinyl]methyl, 3-pyrrolidinyl, 4-piperidinyl, (3-piperidinyl)methyl; R2 = alkyl, oxaalkyl, etc.] were disclosed as selective 5-HII-like agonists useful in the treatment of nigraine, cluster headache, chronic paroxysmal hemicrania and headache assoed, with vascular disorders. A specifically claimed example compd. is 5-{3-hydroxybutyl}-3-{R}. [R]. [I 143322-5]. R1: RCT {Reactant} [neron. of (pyrrolidinylmethyl]ndoles 5-HII-like agonists)

ki: KI (Reactant) (prepn. of (pyrrolidinylmethyl)lndoles 5-HTI-like agonists) IT 143322-46-7P 153435-71-3P 153435-73-5P 153525-35-0P 153525-50-9P 153525-51-0P 167303-56-6P 167303-17P 167303-36-0P 167303-55-1P 167303-56-2P 167303-63-1P 167303-44-2P 167303-66-4P 167303-67-5P 167303-71-1P

L6 ANSWER 5 OF 180 CAPLUS COPYRIGHT 1996 ACS
1995:685346 Document No. 123:313894 Z-Y-ZH compounds as potential
1,3-dipoles. Part 44. Asymmetric 1,3-dipolar cycloaddition reactions
of inines and chiral cyclic dipolarophiles. Cooper, Daniel M.;
Grigg, Ronald; Hargreaves, Simon; Kennevell, Peter; Redpath, James
(Sch. Chem., Leeds Univ., Leeds, 152 9JT, UK). Tetrahedron, 51(28),
7791-808 (English) 1995. COOEM: TETRAB. ISSN: 0004-0020.
A8 Metallo-1,3-dipoles generated in situ from both aryl and aliph.
Imines of .alpha-maino esters by the action of silver salts and
tertlary anines undergo cycloaddn. at room temp. to give
(menthyl)furo[3,4-c]pyrrolecarboxylates pyrrolopyrrolecarboxyates.
.pi.-interaction between the dipolarophile carboxyl group and the
aryl group in the aryl intines is not required for good induction.
The stronger the base the faster the cycloaddn. with
Z-t-butyl-1,1,3,3-tetranethylguanidine > 08U > MEEJ. X-ray crystal
structures of representative cycloadducts established the abs.
configuration of the pyrrolidine stereocenters.
II 170027-89-1P 170027-95-99
RL: SPM (Synthetic preparation); PREP (Preparation)
(prepn. of)

08/466,644 Page 17

- ANSWER 6 OF 180 CAPILIS COPYRIGHT 1996 ACS
- AMSWER 6 OF 180 CAPUS COPPRIGHT 1996 ACS
 in1905 Document No. 123:41025 Opportunities and limitations of
 modern TLC/HPTLC in the quality control of L-tryptophan. Jork,
 Hellaut; Ganz, Jutta (Department Pharmacy und Stological Chemistry,
 University Samarland, Saarbrucken, 66041, Germany, L-Tryptophan;
 Curr. Prospects Med. Drug Saf., 338-50. Editor(s): Kochen, Walter;
 Steinhart, Hans. de Gruyter: Berlin, Germany. (English) 1994.
 CDDFa. 611269.
- Curr. Prospects Med. Drug Saf., 338-50. Editor(s): Kochen, Walter; Steinhart, Hans. de Gruyter: Berlin, Germany. (English) 1994. CODEs: 6J3RA9. Ascending, one-dimensional development of chromatograms was carried out on Chiralplates (10 x 20 cm) in a trough chamber with chamber sath. The mobile phase was acetonitrile-methanol-water (40-10-10, vol./vol./vol./v). The chromatog, was completed after 10 min (distance run 6 cm). The zones were stained by dipping (1 s) in a ninhydrin soln. and heating to 110.degree. for 5 min. Blush-red zones were produced on colorless backgrounds for L-tryptophan, D-tryptophan, and 1,1'-ethylidene-bis(L-tryptophan, Only the two distarencemers 3-carboxy-1-3-indolylatehyl)-1,2,3,4-tetrahydro-beta-carboline were stained ochre yellow. The selectivity of thin-layer chromatog. sepn. is so great that L-and D-tryptophan and 1,1'-ethylidene-bis(L-tryptophan) can be sepd. excellently. Nor is there any difficulty in sepg. L-tryptophan, 1,1'-thylidene-bis(L-tryptophan), 3-carboxy-1-methyl-1,2,3,4-tetrahydro-beta-carboline. 184068-18-2 184203-07-0 Rt. ANT (Analyte): ANST (Analytical study)
 (opportunities and limitations of modern TLC/HPTLC in the quality control of L-tryptophan)
 - control of L-tryptophan)

. . .

- Answer 8 OF 180 CAPLUS COPYRIGHT 1996 ACS
 5:59880 Document No. 122:306133 Effect of a 5-HII receptor
 agonist, CP-122,288, on edema formation induced by stimulation of
 the rat saphenous nerve. Kajekar, Radhika; Gupta, Paul; Shepperson,
 Micholas B.; Brain, Susan D. (Vascolar Biology Research Centre,
 King's College, London, SNJ GAL, UK). Br. J. Pharmacol., 115(1),
 1-2 (English) 1995. CODEN: BJPCBN. 155N: 0007-1188.
 Meurogenic edema formation in the rat hind paw skin induced by elec.
 Stimulation of the saphenous nerve and neasured by extravasation of
 [1251]-albumin, was inhibited by the 5-HIIB receptor agonist,
 CP-93,129, and the novel tryptamine analog, CP-122,288 Significant
 inhibition of up to 66k of control was obsd. with CP-122,286 (2
 .times. 10-14 2 .times. 10-7 mol kg-1] and CP-93,129 (5 .times.
 10-7-5 .times. 10-6 mol kg-1), with the ain. ED for CP-122,288 being
 about 107 fold less than that for CP-93,129. Edema formation
 induced by the intradermal administration of exogenous mediators
 (substance P and histamine) in rat dorsal skin was not inhibited by
 CP-122,288 (2 .times. 10-10 mol kg-1). These results suggest that
 CP-122,288 is a potent inhibitor of neurogenic inflammation in rat
 skin and that the effect any be due to a prejunctional inhibition of
 neuropeptide release.
- skin and that the effect may be due to a prejunctional imminition of neuropeptide release.

 11 143321-74-8, CP-122288
 RL: BAC (Biological activity or effector, except adverse); THU
 [Therapeutic use]; BIOL (Biological study); USES (Uses)
 [neurogenic edema inhibition by 5-HII receptor agonist CP-122288)

L6 ANSWER 7 OF 180 CAPLUS COPYRIGHT 1996 ACS
1995:575044 Document Mo. 122:209995 Differentiating Penicillium
species by detection of indole metabolites using a filter paper
method. Lund, F. (Department of Biotechnology, Technical University
of Oenmark, Lyngby, Den.). Lett. Appl. Microbiol., 20(4), 228-31
(English) 1995. CODER: LAMIET. ISSN: 0266-0254.
AB The indole secondary metabolites chaetoglobosin C, cyclopiazonic
acid, isofumigaclavine A and rugulovasine A and B produced by
several Penicillium species growing on Crapek yeast autolyzate agar
were detected directly in the culture using filter paper wetted with
Ehrlich reagent dissolved in ethanol. The filter paper was placed
on the mycelial side of an agar plug and the metabolites were
visualized as a violet zone on the paper within 10 ain. It was
shown that the combined characters of the violet reaction on filter
paper and the ability to grow on creatine sucrose agar occurred in 5
out of 16 species of Penicillium examd. A few addnl. single
morphol. and physiol. criteria were then sufficient for
identification of P. camenberti, P. commune, P. discolor, P.
expansum and P. roueforti var. rouqueforti.
II 50645-76-8, Chaetoglobosin C
RI: ANI (Analyte), ANIS (Analytical study)
(Differentiating Penicillium species by detection of indole
metabolites using a filter paper method)

L6 ANSWER 9 OF 180 CAPLUS COPYRIGHT 1996 ACS
1995:521096 Document No. 122:310000 High-performance liquid chromatography comparison of supercritical-fluid extraction and solvent extraction of nicrobial fermentation products. Cocks, Simon; Wrigley, Stephen K.; Chicarelli-Robinson, M. Ines; Smith, Roger M. (Xenova Ltd, 240 Bath Road, Slough Berkshire, SL1 4EQ, UX). J. Chromatogr., A, 697(1 * 2), 115-22 (English) 1995. CODEN: JCRAEY.

J. Chromatogr., A, 09/(1 * 2), 113-62 [Engine] 17773. Cooch.
JCRARY.
The use of supercrit. fluids for the extn. of biol. active compds.
from the biomass of atcrobial ferms. has been compared with extn.
using the org. solvents methanol and dichloromethane. Compds.
representing a range of structural types were selected for
investigation. All the exts. obtained were examely preversed-phase
RPLC. The extractability of metabolities using unmodified and
nethanol-modified supercrit.-fluid carbon dioxide was examd. in
particular detail for six microbial metabolities: chaetoglobosin A,
nycolutein, lutecreticulin, 7,8-dihydro-7,8-epony-1-hydroxy-3hydroxymethylxanthone-8-carboxylic acid Me ester, sydowinin B and
elaiophylin. The extn. strength of supercrit.-fluid carbon dioxide
alone appeared to be lower than that of dichloromethane. All the
components of interest that were extractable with dichloromethane
and methanol were also extractable with methanol-modified carbon
dioxide.

and methanol were also cantended.

dioxide.

II 50335-03-09, Chaetoglobosin A

RL: PUR (Purification or recovery); PREP (Preparation)
(#PLC comparison of supercrit.-fluid vs. solvent extn. of
nicrobial fermn. products)

ANSWER 10 0F 180 CAPLUS COPYRIGHT 1996 ACS ::517652 Document No. 123:33479 Synthesis of Aristotelia-type alkaloids. Part XY. Total synthesis of (-)-hobartinol. Dobler, Markus; Anderson, James C.; Juch, Mathias; Borschberg, Hans-Juerg (Lab. Org. Chem., Eidgenoessischen Tech. Rochschule, Zurich, CH-8075, Sytt.). Helv. Chim. Acta, 78(2), 292-300 (English) 1995. CODEM: HCACAY. 155M: 0018-019X.

AB Synthetic (+)-makomakine was transformed in six steps into

(+)-[17R,18R]-17,18-dihydrohobartine-17,18-dio] ((-)-1) with an

overall yield of 38%. This compd. was shown to be identical with

natural hobartinol, a monoterpene indole alkaloid from Aristotelia

australasica, originally believed to be the [17S]-epimer. At the

same time, the synthesis of (+)-I delineates the hitherto unknown

abs. configuration of this metabolite.

II 31869-90-4P, (-)-Hobartinol

RL: PPP (Properties); SPM (Synthetic preparation); PREP

(Preparation)

(total synthesis of hobartinol)

II 153812-73-PI 153812-32-6P

RL: RCI (Reactant); SPM (Synthetic preparation); PREP (Preparation)

(total synthesis of hobartinol)

II 153812-33-7P 153956-17-0P

RL: SPM (Synthetic preparation); PREP (Preparation)

RL: SPN (Synthetic preparation); PREP (Preparation)
(total synthesis of hobartinol)

ANSWER 12 OF 180 CAPLUS COPYRIGHT 1996 ACS
5:466381 Document No. 122:255183 The pre- and postjunctional
activity of CP-122,288, a conformationally restricted analog of
sumatriptan. Beattle, David T.; Connor, Helen E. (Pharmacology II,
Glavo Research and Development Ltd., Park Road, Mare Herts, SGI2
00P, UK). Eur. J. Pharmacol., 276(3), 271-6 (English) 1995. CODEM:
EJPHAZ. ISSN: 0014-2999.
The present study investigated the pre- and postjunctional activity
of CP-122,288 (5-methyl-mainosulfomylmethyl-2-(M-methylpyrrolidin-2Ryl-methyl)-11 -indole), an analog of the vascular 5-HII receptor
agonist, sumatriptan. CP-122,288 inhibited neurogenic plasma
protein extravasation in rat dura with a potency approx. 40 000-fold
greater than sumatriptan (1950 values of 0.3 pmol/kg and 13.9
mmol/kg 1.v. resp.). However, CP-122,288 was only approx. 2-fold
more potent than sumatriptan at inhibiting neurogenically mediated
contractions of the dog saphenous vein. CP-122,288 contracted the
dog saphenous vein and basilar artery with a potency approx. 2-fold
greater than that of sumatriptan. Both compds. possessed similar
affinities at either human 5-HIID.apha. or 5-HIID.beta. receptors.
It is concluded that CP-122,288 exhibits a prejunctional selectivity
in the meninges to inhibit dural plasma protein extravasation
independent of 5-HIID.apha. and 5-HIID.beta. receptor activation.
143321-74-8, CP-1222288

IT 143321-74-B. CP-122288

RI. BAC (Biological activity or effector, except adverse); BIOL (Biological study) (pre- and postjunctional activity of CP-122,288, a conformationally restricted analog of sumatriptan)

Page 18

AMSWER 11 OF 180 CAPLUS COPYRIGHT 1996 ACS
95:502550 Document Mo. 123:228024 Trapping of ininiums by the indole nucleus during catalytic hydrogenation of nitriles: a rapid synthesis of tetrahydro-.beta.-carbolines. Diker, Khalid; Doce de Maindreville, Mitchel; Levy, Jean (Raculte Pharmacle, Universite Reias Champagne-Ardenne, Reias, F-51096, Fr.). Tetrahedron Lett., 36[14], 249-500 (English) 1995. CODER: TELEAY. ISSN: 0040-4039. Reductive self-condensation of indoleacetonitrile upon catalytic hydrogenation over Pd-C in acetic acid yielded 1-(3-indoly)methyl)-1,2,3,4-tetrahydro-.beta.-carboline. Hydrogenating 3,4-dimethoxyphenylacetonitrile failed to give tetrahydropapaverine, but a cross reaction between indoleacetonitrile and 3,4-dimethoxyphenylacetonitrile allowed isolation of 1-{3,4-dimethoxyphenyl-1,2,3,4-tetrahydro-.beta.-carboline, which was also prepd. (76 A) by catalytic hydrogenation of a mixt. of tryptamine and 3,4-dimethoxyphenylacetonitrile. Besides an easy access to the yohidama skeleton, the reaction opens the way to a useful general synthesis of tetrahydro-.beta.-carbolines.

useful general synthesis of tetrahydro-.beta-.carbolines.

11 168209-33-4P
Rl: RCI (Reactant); SPM (Synthetic preparation); PREP (Preparation)
(synthesis of tetrahydrocarbolines by catalytic hydrogenation of nitriles}

IT 168209-35-6P

RL: SPM (Synthetic preparation); PREP (Preparation)
(synthesis of tetrahydrocarbolines by catalytic hydrogenation of
nitriles)

L6 ANSWER 13 OF 180 CAPLUS COPYRIGHT 1996 ACS

1995:421524 Document No. 122:205025 Suppression by the sunatriptan analog, CP-122,288 of c-fos immunoreactivity in trigestnal nucleus caudalis induced by intracisternal capsaich. Cutrer, F. Michael; Schoenfeld, David; Limmroth, Volker; Panahian, Nariman; Moskowitz, Michael A. (Harvard Med. Sch., Nassachusetts Gen. Hosp., Boston, M., 02114, USA). 8r. J. Pharmacol., 114(5), 987-92 (English) 1995.

CODEN: BDPCBM. ISSN: 0007-1188.

A8 The effects of an i.v. administered sumatriptan analog were exand. on c-fos-like immunoreactivity (c-fos-tl), a marker of neuronal activation, evoked within trigenian nucleus caudalis (TMC) and other brain stem regions 2 h after intracisternal injection of the irritant, capsaicin (0.1 mo, 0.1 md), in pentobarbitone-anesthetized Hartley guinea pigs. C-fos-tl was assessed in eighteen serial sections (50. mu.m) using a polyclonal antiserum. A weighted av., reflecting total expression within lamina 1, 110 of TNC was obtained from three representative levels (i.e., at -0.225 mm, -2.475 mm and -6.075 mm). Capsaicin caused significant labeling within lamina 1, 110, a region contp. axonal terminatins of small unayelinated C-fibers, as well as within the nucleus of the solitary tract, area postrema and medial reticular nucleus. A shallar distribution of pos. cells was reported previously after intracisternal injection of other chem. irritants such as autologous blood or carrageenin. Pretreatment with a conformationally restricted sumatriptan analog (with some selectivity for 5-mlls and 5-mll neceptor subtypes) CP-122,288, reduced the weighted av. by approx. 50-60k (P < 0.05) in lamina 1, 110 at 100 pool kg-1, i.v., but did not decrease cell no. within area postrema, nucleus of the solitary tract or medical reticular nucleus. A shallar pattern was reported previously following sumatriptan, dhydroreogratanie or CP-93,129 administration after noxious meningeal stimulation. We conclude that modifications at the amino-ft side chain of sumatriptan drama

3321-74-8, CP-122288
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (suppression by sumatriptan analog, CP-122,288 of c-fos immunoreactivity in trigoninal nucleus caudalis induced by intracisternal capsaicin)

L6 AMSWER 14 OF 180 CAPLUS COPYRIGHT 1996 ACS
1995;377349 Document No. 122:240108 Microbial hydroxylation of some
synthetic Aristotelia alkaloids. Dobler, Markus; Borschberg,
Hans-Juerg (Lab. Org. Chem., Eldgenoesschen Tech. Hochsch., Zurich,
CH-8092, Switz.). Tetrahedron: Asymmetry, 6(1), 213-20 (English)
1995. CODEM: TASYEJ. ISSN: 0957-4166. OTHER SOURCES: CASREACT
1222:4011


AB Synthetically prepd., optically pure samples of the rare Aristotelia alkaloids (+)-makomakine (||), (-)-hobartine, and (+)-aristoteline, were exposed to twelve selected (magal strains and have been shown to afford, sometimes in preparatively acceptable yield, known, as well as hitherto unknown hydroxylated derivs. thereof.

[1 16233-71-39 162333-72-49 162333-73-59

182428-48-0P
RI: BPR (Stosynthetic preparation); BIOL (Biological study); PREP
(Preparation)
(aicrobial hydroxylation of some synthetic Aristotelia alkaloids)
II 73004-61-2, (-)-Hobartine 79559-56-1,
(-)-Makomakine
RI: RI (Reactant)
(aicrobial hydroxylation of some synthetic Aristotelia alkaloids)

```
ANSWER 15 OF 180 CAPLUS COPYRIGHT 1996 ACS
160906-86-59 160906-87-6P 160906-95-6P
160906-96-7P 160906-97-8P 160907-00-6P
 160907-08-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for arylindole serotoninergic agonist)
IT 160906-56-9P 160906-57-0P 160906-58-1P
160906-59-2P 160906-60-5P 160906-61-6P
160906-62-7P 160906-63-8P 160906-68-3P
160906-65-0P 160906-66-1P 160906-68-3P
160906-69-4P 160906-72-9P 160906-73-0P
160906-74-1P 160906-72-P 160906-73-0P
160906-80-9P 160906-75-2P 160906-94-SP
160907-03-9P
RL: SPN (Synthetic preparation): PREP (Preparation)
160907-03-9P
RL: SPM (Synthetic preparation); PREP (Preparation)
(prepn. of, as serotoninergic agonist)
II 151272-88-7
RL: RCI (Reactant)
(reactant for arylindole serotoninergic agonist)
II 160907-09-5
                     RL: RCT (Reactant)
(serotoninergic agonist)
```

L6 ARSWER 15 OF 180 CAPLUS COPYRIGHT 1996 ACS
1995:354225 Document No. 122:133200 5-arylindole derivatives and their
use as serotonin (5-HTI) agonists. Macor, John Eugene (Pfizer Inc.,
USA). PCI Int. Appl. NO 9410171 Al 940511, 72 pp. DESIGNATED
STATES: W: AU, BR, CA, CZ, JP, KR, NO, NZ, PL, RU, US; RN: AT, BE,
CH, DE, DN, ES, FR, GB, GR, IE, IT, LU, NC, NL, PT, SE. (English).
CODER: PIXXOZ. APPLICATION: NO 93-US9790 931019. PRIORITY: US
92-970758 921102.



AB The title compds. I (RI = aninoalkyl; R2-R5 = H, alkyl, aryl, etc.) were disclosed. I are useful in treating migraine and other disorders; they are useful psychotherapeutics and are potent serotonin (5-HT)) agonists and benzodiazepine agonists and analyonists and app be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, algraine, pain and chronic paroxysmal hemicrania and headache assocd. With vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. I are also useful as centrally acting anthypertensives and vasodilators. A specifically claimed example compd. is 5-cyano-1-[[3-[1-(2-nethoxyethyl)-2-pyrolidiny]]aethy]-5-indolyl]-1H-benzimidazole (11).

IT 160907-04-0P 160907-05-1P 160907-06-2P
180907-07-1P
RI: SPM (Synthetic preparation): PREP (Preparation)

160907-07-3P
RL: SPM (Synthetic preparation); PREP (Preparation) (prepn. of)
I 43122-01-4P 1812172-89-8P 151272-90-1P
151272-99-0P 151273-00-6P 151273-01-7P
151273-05-1P 151273-06-2P 151273-07-3P
151273-08-4P 151273-11-9P 153752-55-5P
160906-44-5P 160906-45-6P 160906-45-7P
160906-51-3P 160906-51-4P 160906-54-7P
160906-50-3P 160906-51-4P 160906-54-7P 160906-55-8P 160906-81-0P 160906-82-1P 160906-83-2P 160906-84-3P 160906-85-4P

3321-74-87 13321-74-27 RIL: SPM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (Indole derivs. for treatment of disorders from deficient serotonergic neurotransmission)

08/466,644 Page 20

ARSWER 17 OF 180 CAPLUS COPTRIGHT 1996 ACS
55:191714 Document No. 122:106219 Synthesis of Aristotelia-type
alkaloids. Part XIV. total synthesis of (+)-aristolone. Dobler,
Rarkus; Borschberg, Hans-Juerg (Lab. Org. Chem., Eidgenoessischen
lechmischen Hochschule, Zurtch, CH-8092, Switz.). Tetrahedron:
Asymmetry, 5(10), 2025-22 (English) 1994. CODER: IASYE3. ISSN:
0957-4166. OTHER SOURCES: CASREACT 122:106219.

The first total synthesis of the highly functionalized monoterpenoid indole alkaloid (*)-aristolone (1) is described. This investigation uncovered the hitherto unknown relative and abs. configuration of this rare metabolite which had been isolated before by others in ppm-ants. From Aristotelia australasica. Dehydration of synthetic l lot or readily separable mixt. of the two alkaloids 11,12-didehydro-1-oxomakomakine and 11,12-didehydro-1-oxomakomakine and 11,12-didehydro-1-oxomakomakine which had been isolated in 1988 from A. chilensis.

11 79559-56-1P, (+)-Makoakine
RI: RCI (Reactant); SPM (Synthetic preparation); PREP (Preparation)
(total synthesis of aristolone)
11 99655-77-3P 159979-19-8P 159979-26-7P

RL: SPM (Synthetic preparation); PREP (Preparation) (total synthesis of aristolone)

L6 AMSWER 19 OF 180 CAPLUS COPYRIGHT 1996 ACS
1994:881120 Document No. 121:281120 The synthesis of
alpha.-(3-indoly)methyl)proline-containing compounds as CCK
ligands: analogs of PD-134308. Kendrick, David A.; Ryder, Hamish;
Semple, Graeme; Sheppard, Andrew: Szelke, Michael (Res. Cent.,
Southampton Univ., Southampton, 501 7MP, WK). Pept. 1992, Proc.
Eur. Pept. Symp., 22nd, Meeting Date 1992, 579-80. Editor(s):
Schneider, Conzal M.; Eberle, Alex N. ESCOM: Leiden, Neth.
(English) 1993. CODEN: SOLUAM.

AB A report from a symposium on the stereoselective prepn. of analogs I (Adoc = 2-adamantyloxycarbonyl) which have and .alpha.-{3-indolylmethyl)proline residue in place of the .alpha.-methyl-D-trybtophan of PD 13430B.

II 158873-11-LDP, peptides contg.
RL: RCI (Reactant): SPM (Synthetic preparation); PREP (Preparation) (asym. synthesis of .alpha.-(3-indolylmethyl)proline-contg. peptides as analogs of PD 13430B)

II 158873-12-2DP, derivs.
RL: SPM (Synthetic preparation); PREP (Preparation) (asym. synthesis of .alpha.-(3-indolylmethyl)proline-contg. peptides as analogs of PD 13430B)

L6 AMSWER 18 OF 180 CAPLUS COPYRIGHT 1996 ACS
1995:15157 DOCUMENT MO. 122:9327 Stoichiometrically sensitized
decarboxylation occurring in a mol. crystal composed of
phenanthridine and 3-indoleacetic acid. Koshina, Hideko; Ding,
Kuilling; Matsuura, Teruo (Fac. Sci. Technology, Ryukoku Univ.,
Otsu, S20-21, Japan). J. Chem. Soc., Chem. Comzun. (18), 2053-4
(English) 1994. CODEN: JCCCAT. ISSN: 0022-4936. OTHER SOURCES:

IT 159617-53-5P
RL: BYP (Byproduct): PREP (Preparation)
(stoichionetrically sensitized decarboxylation occurring in a
mol. crystal composed of phenanthridine and indoleacetic acid)

L6 AMSWER 20 OF 180 CAPLUS COPYRIGHT 1996 ACS
1994:680497 Document No. 121:280497 Use of 2,5-Dimethylpyrrole as an Amino-Protecting Group in an Efficient Synthesis of 5-Amino-3-[(N-methyl-pyrrolidin-2(R)-yl)methyl]indole. Macor, John E.; Chenard, Bert L.; Post, Romald J. (Department of Medicinal Chemistry, Pfizer Inc., Groton, CT, 06340, USA). J. Org. Chem., 59[24), 796-8 (English) 1994. CODER: JOCKAH. ISSN: 0022-3263. OTHER SUDRESS: CASREACT 121:280497; CLACS-IMAGE; CLACS.
AB 5-Amino-3-(M-methylpyrrolidin-2R-ylmethyl)indole was synthesized in an overall of 39% in four steps on a large scale. Cructal to the success of this sequence was the use of a 2,5-dimethylpyrrole as the protecting group for the 5-aminoindole functionality. This protecting group for the 5-aminoindole functionality. This protecting group or the 5-aminoindole functionality. This protecting group was stable to (unreactive toward) ethylmagnesium bromide, a hindered acid chloride (CEZ-proline acid chloride), and lithium aluminum hydride, but eastly removed in high yield using unique conditions (hydroxylamine hydrochloride/triethylamine/propano 1/water/.DELTA.).

II 158752-53-39
RI: SRC (Reactant); SPM (Synthetic preparation); PREP (Preparation) (use of dimethylpyrrole as an amino-protecting group in an efficient synthesis of amino[(methylpyrrolidinyl)methyl]indole]
II 143322-01-49
RI: SPM (Synthetic preparation); PREP (Preparation)

IT 143322-01-4P

system (synthetic preparation); PREP (Preparation)
(use of dimethylpyrrole as an amino-protecting group in an
efficient synthesis of amino[(methylpyrrolidinyl)methyl]indole)

08/466,644 Page 21

AMSWER 21 OF 180 CAPLUS COPPRIGHT 1996 ACS
8:831780 Document Mo. 121:231780 Mon-decarboxylative 1,3-dipolar
cycloadditions of infines of .alpha.-aaino acids as a route to
proline derivatives. Aly, Moustafa F.; Younes, Mansour I.;
Metvally, Saoud A. M. (Fac. Sci., Assiut Univ., Qena, Egypt).
Tetrahedron, 50(10), 3159-88 (English) 1994. CODER: TETRAB. ISSN: 0040-4020. OTHER SOURCES: CASREACT 121:231280.

- A8 The 1,3-dipolar cycloaddn. reaction of alanine with salicylaldehyde and M-substituted maleinides I (R = Me, Ph) gave stereospecific cycloadducts II. The 1,3-dipolar cycloaddn. reaction of .alpha.-maino acids with anyl aldehydes in the presence of di-Me fumarate gave isomeric cycloadducts III (Ar = 2-bydroxyphenyl, R] = Me, H, CHZCHMZ, CHZCHZSMe, CHZPh, indol-3-ylacthyl; Ar Ph, 2-methoxyphenyl, 2,4-dimethoxyphenyl, R] = Me) and IV (Ar and R] = same). The relatively low yield in the case of di-Me fumarate is presumably due to the steric interaction between the dipolarophile and the substituents at both ends of the dipole.

 II 158134-75-99 158249-37-7P
 RL: SPM (Synthetic preparation): PREP (Preparation)
 - RL: SPN (Synthetic preparation): PREP (Preparation) (prepn. of)

L6 AMSWER 23 OF 180 CAPLUS COPYRIGHT 1996 ACS
1994:483048 DOCUMENT NO. 121:83048 (ACYLANINO) INDOIR DEFIVATIVES aS
5-HI agonists. Macor, John E. (Pfizer Inc., USA). PCI Int. Appl.
W0 9321180 A1 931028, 32 pp. DESIGMATED STATES: W. AU, BR, CA, CZ,
DE, JP, KR, NO, NZ, PL, RU, SK, UA, US; RW: AT, BE, CH, DE, DK, ES,
FR, GB, GR, IE, ITI, UN, MC, NL, PT, SE. (Eqplish). CODER: PIXXOZ.
APPLICATION: W0 93-US1807 930304. PRIORITY: US 92-866382 920410.

- A8 The title compds. I [R1 = H, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, (un)substituted aryl, etc.; R2 = CF3, C1-6 alkyl, aryl, C1-3 alkylaryl, etc.; R6 = H, OH, alkoxy, aryloxy, acylanino, etc.; M, Y = anino acid residue; n = 0, 1; n = 0-2], which are 5-H1 agonists (no data), useful in the treatment of hypertension (no data), depression (no data), anxiety (no data), pain (no data), etc., are prepd. Thus, M-benzyloxycabonylglycine was coupled with 5-anino-3-(M-methylpyrrolidin-2R-ylnethyl)-1H-indole, producing 5-(M-benzyloxycarbonylglycyl)anino-3-(M-methylpyrrolidin-2R-ylnethyl)-1H-indole in /A4 yield.

 [11 14321-38-81 143122-01-4 151272-89-8 154038-85-8 154038-83-2 154038-83-3 154038-85-8
- 154038-86-5 RL: RCT (Reactant)

- (prepn. as serotoninergic receptor agonist) IT 143321-58-8 143322-01-4 151273-38-0
- RE: RCT (Reactant)
 (reactant, in prepn. of (acylamino)indole serotoninergic receptor

L6 ANSWER 22 OF 180 CAPLUS COPYRIGHT 1996 ACS
1994:574790 Document No. 121:174790 Antifungal substances produced by Chaetosius globosum. Amesiya, Toshimiti; Kondo, Akihiro; Mirano, Kazuya; Hirukawa, Toshimusi; Kato, Tadahiro (Fac. Mortic., Chiba Univ., Matsudo, 271, Japan). Chiba Daigaku Engelgakub Gakujutsu Hokoku, 48, 13-18 (Japanese) 1994. CDDEM: CDEGAF. ISSN: 0069-3227.

AB Antifungal substances were extd. From culture filtrate of the most untagenistic isolate identified as Chaetosium globosum. Two active substances were obtained by using silica gel column chromatog. and high performance liq. chromatog. By analyzing with mass spectrometer (EINS, NR-MS), IM-MRM and ISIC-MRM, the major substance was identified as Chaetoglobosin A, one of the toxic metabolites produced by C. globosum and C. chochitodes. Another substance was assumed to have sailar structure with Chaetoglobosin A. The major substance completely inhibited the spore germination of V. dahlise at 32. au. g/ml. It was also active against V. albo-atrum and Rhizoctonia solani, but not against Fusarium oxysporum, F. solani and Pythium aphanidermatum.

11 50335-03-0, Chaetoglobosin A
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(from Chaetomium globosum, antifungal activity of, against Verticillium and Rhizoctonia)

L6 AMSWER 24 OF 180 CAPLUS COPYRIGHT 1996 ACS
1994:473079 DOCUMENT NO. 121:73079 5-[(3-Mitropyrid-Z-yl) amino] Indoles: Movel Serotomin Agonists with Selectivity for the 5-HID Receptor. Variation of the C3 Substituent on the Indole Template Leads to Increased 5-HID Receptor Selectivity. Macor, John E.; Blank, David H.; Fox, Carol B.; Lebel, Lorraine A.; Mewman, Michael E.; Post, Ronald J.; Ryan, Kevin; Schmidt, Anne M.; Schulz, David W.; Koe, B. Kenneth (Department of Medicinal Chemistry, Pfizer Inc., Groton, CI, 06340, USA). J. Med. Chem., 37(16), 2509-12 (English) 1994. CODEN: JMCHAR. ISSN: 0022-2623. OTHER SOURCES: CASREACI 121:73079; CAMSC-MACE; CJACS. CASREACT 121:73079; CJACS-IMAGE; CJACS.

AB A series of 5-{3-nitropyrid-2-ylamino}indoles () has been AB A series of 5-(3-nitropyrid-2-ylanino)indoles () has been synthesized which contain 2-aninoethyl side chains at C3 of the indole with varying degrees of conformational constraint. These compds. show different degrees of selectivity for the 5-HIID receptor, depending on the C3 substituent. The major effect on binding and functional activity appears to be with variation of affinity and potency for the 5-HIID receptor. The compd. most selective for the 5-HIID receptor in this series is I.

11 143321-58-8P 151273-38-0P

II 143221-58-89 151273-38-0P
RI: RCI (Reactant); SPM (Synthetic preparation); PREP (Preparation)
(prepn. and deprotection of)
II 143322-014-9151272-99-8P
RI: RCI (Reactant); SPM (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with chloronitropyridine)
II 151272-88-7P 151272-90-1P

RECEIVED TO SUBJECT OF THE PROPERTY OF STRUCTURE IN relation to)

Page 22

L6 AMSWER 25 OF 180 CAPLUS COPYRIGHT 1996 ACS
1994:457330 DOCUMENT NO. 121:57330 Preparation of indole derivatives
as 5-H71-11ke agonists. Macor, John Eugene; Wythes, Martin James
(Pfizer Ltd., UK; Pfizer Inc.; Pfizer Research and Development Co.,
N.V./S.A.). PCI Int. Appl. WO 932:1177 A1 931028, 70 pp. 0ESIGMATED
574165: W: AU, BR, CA, CZ, FI, HU, JP, KR, MO, NZ, PL, KU, SK, UA,
US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT,
SE. (English). CODES: PIXXOZ. APPLICATION: WO 93-EP738 930325.
PRIORITY: GB 92-7930 920410.

AB Title compds. I [R] = (C]-6 acyl)-Cl-3 alkylene, (C]-6 alkyl-O2C)-Cl-3 alkylene, (R2MCC)-Cl-3 alkylene, (R2MCC)-Cl-3 alkylene, (R2MCC)-Cl-3 alkylene, (R2MCC)-Cl-3 alkylene, (R0) C3-7 cycloalkyl, (aryl) C3-6 alkenyl, heteroaryl-Cl-3 alkylene etc.; R2 = N, halo, F3C, NC, R2MCC, NO, etc.; k = 0-2] or a salt thereof, are prepd. 5- (Z-thylsulfonylethyl)-3-(Z-pyrrodlaylaethyl)-HN-Indole (prepn. glven) was reacted with Z-pyridylaethyl)-Horide to give [R] = 2-pyridylyaethyl, R2 = Z-ELSGZCHZCRZ, k = 1]. A staflar prepd. I [R] = ELCGCHZ, R2 = ELSGZCHZCRZ, k = 1] - a valuated for max. contraction on saphenous vein strip showed an ECSO = 3.1. times. 10-3M.

II 433122-48-9 F153435-71-3F 153525-51-0P
153525-55-4P
R1: RCI (Reactant): SPM (Synthetic preparation). DRCD (Canadata)

153525-52-1P 153525-53-2P 153525-54-3P
153525-55-4P
RL: RCT (Reactant); SPM (Synthetic preparation); PREP (Preparation) (prepn. and reaction of, prepn. of 5-HT1 agonists)
1T 143322-46-7P 143322-47-8P 153525-37-6P
RL: SPM (Synthetic preparation); PREP (Preparation) (prepn. of)
1T 153435-72-4P 153435-73-5P 153525-10-1P
153525-12-4P 153435-73-5P 153525-13-4P
153525-12-7P 153525-16-6P 153525-13-4P
153525-12-7P 153525-16-9P 153525-22-5P
153525-27-3P 153525-18-9P 153525-22-5P
153525-27-6P 153525-27-0P 153525-28-1P
153525-27-6P 153525-37-0P 153525-38-1P
153525-32-7P 153525-33-8P 153525-31-6P
153525-32-7P 153525-33-8P 153525-31-6P
153525-38-P 153525-31-6P 153525-31-6P
153525-38-P 153525-31-6P 153525-31-6P
153525-38-P 153525-31-6P 153525-31-6P
153525-48-1P 153525-36-1P 153525-40-7P
153525-48-1P 153525-36-1P 153525-40-7P
153525-48-1P 153525-48-5P 153525-40-6P

L6 ARSWER 26 OF 180 CAPLUS COPYRIGHT 1996 ACS
1994:298534 Document No. 120:298534 Preparation of inidazole,
triazole, and tetrazole derivatives as 5-HI1-like receptor agonists.
Castro Pineiro, Jose Luis; Castro, Pineiro Jose Luis; Guiblin,
Alexander Richard; Natassa, Victor Giulio; Reeve, Austin John;
Sternfeld, Francine; Street, Leslie Joseph (Merck Sharp and Dohne
Ltd., UK). PCT Int. Appl. W0 9402477 Al 940203, 83 pp. DESIGNATED
STATES: W: AU, CA, JP, US; RW: AT, BE, CH, DE, OK, ES, FR, GB, GR,
IE, IT, U, W.C, Mt, PT, SE. (English). CODEN: PIXXOZ.
APPLICATION: W0 93-GB1495 930715. PRIORITY: GB 92-15721 920724; GB
92-25657 921208. 92-25657 921208.


AB Title compds. [I; the broken circle represents two non-adjacent double bonds in any position in the five-membered ring; Al = H, hydrocarbyl, heterocyclyl, halo, etc.; A2 = groups cited for Al, etc.; E = bond, alkylene; R = heteroaryl group Q; B = O, S, MR3; Rl = 2-pyrrolidinoethyl, 3-aninocyclobutyl, 3-pyrrolidinghtyl, etc.; U = N, CK2; R2, R3 = H, alkyl; Z-4 of V,w,X,Y,Z = N and the other(s) = C (sic)] were prepor . Thus, 1-(4-hydrazinohney)]nethyl-1,Z.4-triazole and 4-{1-azetidinyl}butanal di-Ne acetal (prepn. each given) were subjected to Fischer indole synthesis conditions to give title compd. II. 1 had pECSO of .gtoreq.5.0 for mediation of rabbit saphenous vein contraction.

II 154748-38-67
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and reaction of, in prepn. of 5-HII-like receptor agonist)

II 154748-30-41
RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as 5-HII-like receptor agonist)

L6 ANSWER 25 OF 180 CAPLUS COPYRIGHT 1996 ACS (Continued) ANDER 25 OF 180 CAPLUS CUPINIGHT 1998 ALS (CO 153525-50-9P RL: SPW (Synthetic preparation); PREP (Preparation) (prepn. of, as 5HT) agonist)

L6 AMSWER 27 OF 180 CAPLUS COPYRIGHT 1996 ACS
1994:217347 Document No. 120:217347 The synthesis of
conformationally/rotationally restricted analogs of the
neurotransmitter serotonin. Macor, John E.; Blank, David H.; Post,
Ronald J. (Cent. Res. Div., Pfizer Inc., Groton, CT, 06340, USA).
Tetrahedron Lett., 35(1), 45-8 (English) 1994. CODEN: TELEAY.
155N: 0040-4039. DTHER SOURCES: CASREACT 120:217347.



A8 The novel conformationally/rotationally restricted analogs I and II of the neurotransaitter serotonin which are modeled after the 5-HIZ receptor selective agonist CP-143,474 [a dihydropyrano[3,2-e]indole] were prepd.are described. I was obtained from the pyranoindole and II from 5-indolo].

IT 153969-85-8P

RL: SPM (Synthetic preparation); PREP (Preparation)

ARSWER 28 OF 180 CAPLUS COPYRIGHT 1996 ACS
4:2717271 DOCUMENT RO. 120:217271 Indole derivatives as 5-HT1
agonists. Brown, Alan Daniel; Dickinson, Roger Peter; Mythes,
Martin James (Pfizer Ltd., UK; Pfizer Inc.; Pfizer Research and
Development Co., N.V./S.A.). PCT Int. Appl. WO 922178 AI 931028,
146 pp. OSIGNATED STRIES: N: AN, BR, CA, CZ, FI, HU, DY, KR, MO,
NZ, PL, RU, SK, UM, US; RN: AT, BE, CH, OE, DK, ES, FR, GB, GR, IE,
IT, LU, NC, NL, PT, SE. (English). CODEN: PIXXOZ. APPLICATION: WO
93-EP867 930408. PRIORITY: GB 92-8161 920414. 1994:217271

AB The title compds. I {R = {un}substituted Ph, pyridiny}, pyridaziny}, pyrididiny}, pyraidiny}, pyraidiny}, fury}, thienyi; Rl = H, Cl-6 alky}, C3-7 cycloalky}, C5-7 cycloalky}, C5-6 alkyn}, c5-6 alkyn}, etc.; a = 1, 2], which are selective agonists at the 5-H71-like subtype of the 5-hydroxytryptamine receptor, are prepd. Thus, I {R = 3-C6H4SOZNB2, Rl = He, a = 1} vas prepd. and demonstrated 50% max. contraction of dog-isolated saphenous vein strip at 3.78 X 10-9 M.

II 15344-62-9 153443-66-9 15343-67-4
15344-65-2 153434-66-9 15343-70-9
15344-71-0 153434-72-1 15343-71-5
15343-80-1 53434-81-5 15343-81-7-5
15343-80-1 15343-81-5 15343-81-6
15343-80-1 15343-81-5 15343-81-6
15343-80-1 15343-80-9 15343-81-4
15343-80-1 15343-80-9 15343-91-4
15343-90-15343-90-1 15343-91-4
15343-90-15343-90-1 15343-91-6
15343-90-1 15343-90-1 15343-91-6
15343-00-1 15343-90-1 15343-90-7
15343-00-1 15343-90-1 15343-90-8
15343-00-1 15343-1-1 15343-00-8
15343-00-1 15343-1-1 11 15343-1-215343-1-0 15343-1-1 1 15343-1-215343-1-0 15343-1-1 1 15343-1-215343-1-0 15343-1-1 1 15343-1-215343-1-0 15343-1-1 1 15343-1-215343-1-0 15343-1-1 1 15343-1-215343-1-0 15343-1-1 1 15343-1-215343-1-0 15343-1-1 1 15343-1-215343-1-0 15343-1-1 1 15343-1-215343-1-0 1 15343-1-1 1 15343-1-215343-1-0 1 15343-1-1 1 15343-1-215343-1-0 1 15343-1-1 1 15343-1-215343-1-0 1 15343-1-1 1 15343-1-215343-1-0 1 15343-1-1 1 15343-1-215343-1-0 1 15343-1-1 1 15343-1-215343-1-0 1 15343-1-1 1 15343-1-215343-1-0 1 15343-1-1 1 15343-1-215343-1-0 1 15343-1-1 1 15343-1-215343-1-0 1 15343-1-1 1 15343-1-215343-1-1 1 15343-2-215343-1-2 1 15343-2-215343-1-3 1 15433-2-215343-1-3 1 15433-2-215343-1-3 1 15433-2-215343-1-3 1 15433-2-215343-1-2 1 15343-2-215343-1-2 1 15343-2-215343-1-2 1 15343-2-215343-1-2 1 15343-2-215343-1-2 1 15343-2-215343-1-2-1 15343-2-215343-1-2-1 15343-2-215343-1-2-1 15343-2-215343-1-2-1 15343-2-215343-1-2-1 15343-2-215343-1-2-1 15343-2-215343-1-2-1 15343-2-215343-1-2-1 15343-2-215343-1-2-1 15343-2-2-

15343-2-5-1 (Reactant) Rl: RCT (Reactant) (prepn. as 5-HT1 receptor agonist) 17 143322-46-7 143322-57-0 153435-54-2 153435-55-3 153435-56-4 153435-57-5 153435-58-6 153435-71-3 153435-72-4

ANSWER 29 OF 180 CAPLUS COPYRIGHT 1996 ACS AMSWER 29 OF 180 CAPLUS COPYRIGHT 1996 AC 1910 1005995 DOCUMENT NO. 120106995 Preparation of azole indole derivatives as 5-H11 agonists. Macor, John E.; Mowakowski, Jolanta I. (Pfizer Inc., USA). PCI Int. Appl. MO 9318032 A) 930916, 38 pp. DESIGNATED STATES: N: AU, BR, CA, CZ, DE, JP, KR, MO, MZ, PL, RU, SK, UM, US; NN: AI, BE, CH, DE, DK, ES, FR, GB, GR, IE, II, LU, MC, MI, PT, SE. (English). CODER: PIXXOZ. APPLICATION: MO 93-US1667 930303. PRIORITY: US 92-846640 920305.

AB Title compds. I (A = bond, C1-4 alky1, C1-4 alkeny1; n = 0-2; R1 = N, C1-6 alklary1, ary1, C1-3 alky1heteroary1, R6(EM2)m wherein R6 = MC, F3C, etc., m = 1-3; N, X, Y, Z = 0, S. N, C such that at least one of M, X, Y, Z 18 K; RZ, RZ, RA, RS = H, 01-6 alky1, ary1, C1-3 alky1hy1, C1-3 alky1heteroary1, halo, MC, F3C, OZM, etc.; one of R2R2, R3R4, R4R5 = 5-7-membered alky1 ring, 6-membered alky1 ring, 5-7-membered heteroalky1 having 1 of 0, M, S, etc.; R11 = H, R12O, R12OHM wherein R12 = C1-6 alky1, ary1, C1-3 alky1ary1) an a salt thereof useful as 5-H1, agonists (no data) and in disorders arising from deficient serotonineryic neurotransaission (no data), are prepd. (R)-1 (A = bond, n = 1, R1 = PhCH2O2C, W = S, Z = N, X = Y = C, R2 = R3 = R11 = H, R4 = PhCH2).

Il 1521362-19-1P 1521362-20-4P 1521362-21-5P
RL: RCI (Reactant): SPM (Synthetic preparation): PREP (Preparation) (prepn. and reaction of, in prepn. of 5-H1) agonist)

Il 152362-15-7P 152362-16-8P 152362-17-9P
152362-18-DP 152362-12-8P 152362-33-9P
RL: SPM (Synthetic preparation): PREP (Preparation)

RL: SPM (Synthetic preparation); PREP (Preparation) (prepn. of, as 5-HT1 agonist)

16 ANSWER 28 OF 180 CAPIUS COPYRIGHT 1996 ACS (Continued) 153435-73-5 RL: RCT (Reactant) (prepn. as intermediate in prepn. of 5-HT) receptor agonists) Page 23

L6 AKSWER 30 OF 180 CAPLUS COPYRIGHI 1996 ACS
1994:10876) Document Mo. 120:108761 Indole derivatives as serotonin
receptor (5-HT]] agonists. Macor, John E.; Mythes, Martin J.
(Pfizer inc., USA), PCT Int. Appl. WO 9320073 Al 931014, 43 pp.
DESIGNATED STATES: W: AU, BR, CA, CZ, DE, JP, KR, MO, NZ, PL, RU,
SK, UA, US; RN: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, UJ, MC,
ML, PT, SE. (English). CODEN: PIXXOZ. APPLICATION: WO 93-US1967
930310. PRIORITY: US 92-864737 920407.

AB Three members of claimed indoles 1 [n = 0-2; m = 0-3; w = 7 types of oxo- and/or thioxo-substituted azolidinyl radicals (pyrrolidinyl, inidazolidinyl, oxazolidinyl, thiazolidinyl) with optional addni. substitutents; R1 = H, (hydroxy)alkyl, alkenyl, alkynyl, aryl, alkylaryl (sic, e.g., Ch2Ph), alkyheteroaryl, certain heterofunctional-terminated alkyl; R2 = H, OR3, MHCOR3; R3 = H, alkyl, aryl, alkylaryl], potent 5-H11 agonitats (no data), were prepd. for treatment of hypertension, depression, anxiety, obesity, migraine, etc. For example, Misunobu coupling of the alc. (R)-1-(M-benzyloxycarbonylpyrrolidin-2-yl)-3-hydroxypropene with Z-bromo-4-(Z-oxo-1,3-oxazolidin-4(S)-ylmethyl)-1-(trifluoroacetylamino)benzene at the anide N (100P yield), followed by Pd(OAc)2-catalyzed cycliration to an indole (40%), hydrogenolytic deprotection (69%), and M-alkylation with MeOCHZCH2Br (36%), gave title compd. III.

1143122-57-0P

R1_SPM (Synthetic preparation); PREP (Preparation)

| 1 143322-57-0P | RL 5PH (Synthetic preparation); PREP (Preparation) (Pd-catalyzed coupling; prepn. of indole derivs. as 5-HT] | agonists) | | 152305-14-1P 152305-19-6P 152305-20-9P | 152305-21-0P 152305-24-3P 152305-25-4P | RL 5PH (Synthetic preparation); PREP (Preparation) (intermediate; prepn. of indole derivs. as 5-HT] | agonists) | | 1152305-12-9P 152305-13-0P 152305-22-1P 152305-13-6P | 152305-13-6P |

152305-12-9F 152305-13-UF 152305-12-1F 152305-26-5F RL: SPM (Synthetic preparation); PREP (Preparation) (prepn. of indole derivs. as 5-HT1 agonists)

ARSWER 31 OF 180 CAPLUS COPYRIGHT 1996 ACS
3:662341 Document No. 119:262341 Conformationally restricted
sumatriptan analogs, CP-122,288 and CP-122,638 exhibit enhanced
potency against neurogenic inflammation in dura mater. Lee, Won
Suk; Moskowitz, Mitchael A. (Stroke Research Laboratory, Neurosurgery
and Neurology Services, Nassachusetts General Nospital, Harvard
Nedical School, 32 Fruit Street, Boston, MA, (22114, USA). Brain
Res., 626[1-2], 303-5 (English) 1993. CODEN: BRREAP. ISSN:
0006-8993.
CP-122,288 and CP-122,638 (analogs of sumatriptan in which the
C3-aninoethyl side chain has been modified) blocked plasma protein
extravasation response within dura mater following trigeninal
ganglion stimulation. The threshold (1 and 0.1 pmol/kg, resp.) was
remarkably lower than for sumatriptan (7 nmol/kg), as was the dose
at max. response. As with sumatriptan, substance P-induced plasma
leakage was unaffected by either compd., and metergoline only
partially (27%) reverse the effects of CP-122,288. The data
suggest the importance of modifications at the aninoethyl side chain
to the actions of sumatriptan and possibly to the treatment of
digratine headache.

algraine headache.

143321-74-9, CP 122288 143321-78-2, CP 122638
RL: BIOL (Biological Study)

(neurogenic pachymeningitis-inhibition by, structure in relation

16 AMSWER 33 OF 180 CAPLUS COPYRIGHT 1996 ACS
1993:510509 Document No. 119:110509 20-Ketoreductase activity of chactoglobosin A and prochaetoglobosins in a cell-free system of Chaetomium subaffine and the isolation of new chaetoglobosins.
Olkawa, Mideaki; Murakani, Yasunobu; ichihara, Akitami (fac. Agric., Mokkaido Univ., Sapporo, 060, Japan). Blosci., Biotechnol.,
Blochews., 57(4), 628-31 (English) 1993. CODEM: 8881E3.
AB The conversion of prochaetoglobosins as plausible precursors into mycotoxin chaetoglobosin A in a cell-free system of C. subaffine was unsuccessful. Reductase activity of the 20-keto-analogs, and prochaetoglobosin SI and III were found in a microsonal fraction of this fungi. Two new metabolites of chaetoglobosins, named chaetoglobosin Fex and 20-dihydrochaetoglobosins, named chaetoglobosin Fex and 20-dihydrochaetoglobosin A, were also isolated from the same aircroorganizas. Their structures were elucidated by spectroscopic data and chem. transformation.
Il 189437-95-1 409560-99-5
RL: PROC (Process)
(as chaetoglobosin metabolite of Chaetomium subaffine, formation of)

of) ii 149439-83-8 149439-84-9

| 1 14943-93-8 14943-84-9
R: BIOL (Biological study)
(chaetoglobosins of Chaetomium subaffine in relation to)
IT 5035-0-0-0, Chaetoglobosin A
R: BIOL (Biological study)
(ketoreductase of, of Chaetomium subaffine)
IT 133613-78-2 133625-28-0

RL: BIOL (Biological study)
(of Chaetomium subaffine, ketoreductase in relation to)

L6 AMSWER 32 OF 180 CAPLUS CDPYRIGHT 1996 ACS
1993:649833 Document Mo. 119:249833 Indole derivatives which are
potent serotinin receptor antagonists. Macor, John E. {Pfizer inc.,
USA). PCT Inc. Appl. Wo 9311106 AJ 930510, 65 pp. DESIGNATED
STATES: W: AU, 8R, CA, CS, DE, FI, HU, JP, KR, NO, PL, RU, UA, US;
RN: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, KL, SE.
(English). CDDER: PIXXOZ. APPLICATION: WO 92-US8306 921006.
PRIORITY: US 91-796744 911125.

Page 24

1 01= - N-R7 02= - N-R7

A8 The title compds. I [R] = CH2CH2RRZRB, Q], Q2 (dotted line represents an optional double bond), etc.; R7,88 = H, C1-Galkyl, aryl, C1-3alkylaryl, etc.; x 0, HH, 5; Z = (m)substituted 5- or 6-membered heterocycleo; R788 may form a 4- to 6-membered ring], which are potent serotonin (5-H1) receptor antagonists (modata), useful in the treatment of hypertension fao data), depression (no data), anxiety (no data), eating disorders (no data), obesity (no data), etc., are prepd. Thus, (R)-5-maino-3-(syrrolidin-2-ylmethyl)-1-H-indole vas prepd. by hydrogenolysis of (R)-3-(H-benzyloxycarbonyloyrolidin-2-ylmethyl)-5-dibenzyloxycarbonyloyrolidin-2-ylmethyl)-15127-8-8-B 15127-90-01 F15127-89-00
151273-00-69 151273-01-79 151273-00-09
151273-00-69 151273-01-79 151273-08-49
151273-08-27 151273-07-79 151273-08-49
151273-16-49 151273-17-59 151273-18-69
151273-18-09 151273-00-01 151273-11-79
151273-00-01 151273-01-17-09
RL: SPM (Synthetic preparation); PREP (Preparation) (prepn. and serotonin receptor antagonist activity of)
II 43322-69-3 151273-10-19

13322-06-3 1512/3-10-8
RL: RCT (Reactant)
(reaction of, in prepn. of indole serotonin receptor antagonist)

L6 AMSWER 34 OF 180 CAPLUS COPYRIGHT 1996 ACS
1993:496155 Document No. 119:96155 The use of a proline ring as a
conformational restraint in CCK-8 receptor dipeptoids. Fincham,
Christopher I.; Horwell, David C.; Ratcliffe, Giles S.; Rees, David
C. (Parke-Davis Meurosci. Res. Cent., Cambridge, CB2 208, UK).
Bloory, Med. Chea. Lett., 2(5), 403-6 (English) 1992. CODEM:
BMCLE8. ISSN: 0960-894X.

AB Examm. of mol. dynamics simulations and an x-ray crystal structure of a selective cholecystokinin B (CCK-B) receptor dipeptoid Trp deriv. led to the synthesis of conformationally restrained Pro deriv. 1. The CCK receptor binding of I is described. II 149170-00-3P

II LAVI/O-00-3P

RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and amidation of, with amino(phenyl)propanol)

II 1491/O-01-4P 1491/O-02-5P

RI: SPN (Synthetic preparation); PREP (Preparation) (prepn. and cholecystokinin B receptor binding affinity and selectivity of)

L6 ANSWER 35 OF 180 CAPLUS COPYRIGHT 1996 ACS
1993:253396 Document No. 118:253396 Immunomodulator and antitumor
TAN-1142 and its manufacture with Chaetonium. Tanida, Selichi;
Isuboya, Shigetoshi; Harada, Setsuo (Takeda Chemical Industries,
Ltd., Japan). Jpn. Kokal Tokkyo Koho JP 04350691 A2 921214 Heisei,
6 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 91-136729

Immunomodulator and antitumor TAM-1142 (1) is manufd. by culturing 1-producing Chaetomium sp. C. globosum 1-319 (1FO 32395, FERM BP-3429) was shake-cultured in a medium contg. glucose, dextrin, sophem powder, peptone, yeast ext., and salts at 28.degree. and pH 7.0 for 120 h, and the culture medium (70 t) extd. with AcOEt at pH 3.0 and processed to recover 130 mg 1. I inhibited the growth of murine tumor cell Bib with 50x inhibitory comen. of 0.95 .mu.g/mi. 1 (at 100 mg/kg) did not show acute toxicity in mice.

I (at 100 mg/kg) did not show acute toxicity in mice.
II 147527-31-17, TAM III2
RL: BMF (Bioindustrial manufacture); BIOL (Biological study); PREP
(Preparation)
(manuf. of, with Chaetomium globosum, as immunomodulator and
antitumor agent)

L6 AMSWER 37 OF 180 CAPLUS COPYRIGHT 1996 ACS
1993:168927 DOCUMENT NO. 118:168927 Synthests of a conformationally
restricted analog of the anti-migraine drug sumatriptan. Macor,
John E.; Blank, David H.; Post, Romald J.; Ryan, Kevin (Cent. Res.
Div., Pfizer Inc., Groton, CT, 06340, USA). Tetrahedron Lett.,
33(52), 8011-14 (English) 1992. CODE: TELEAY. ISSN: 0040-4039.
OTHER SOURCES: CASREACT 118:168927.

The synthesis of conformationally restricted sumatriptan analog [(R = Me) (II) is described. The Mitsunobu coupling of hydroxypropene III (BZ = benzyloxycarbonyl) with trifluoroacetanilide IV in the presence of Ph3P and DEAD gave 57k intermediate V, which underwent an intramol. Heck reaction with Pd(DAC)2 in the presence of ELSN in DWC to give θ 1kp protected analog I (R = CB2). A bonus of the latter cyclization was the concomitant loss of the trifluoroacetyl group. I (R = CB2) was reduced with LIAHM4 in refluxing TMF gave θ 5k II. Ill was prepd. from ρ 7cm of ρ 7cm o 11 143321-74-82

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and antisigraine activity of)
17 143321-82-89

PRE: RCT (Reactant); SPM (Synthetic preparation); PREP (Preparation) (prepa. and hydride redn. of)

L6 ARSWER 36 OF 180 CAPLUS COPYRIGHT 1996 ACS


1993:253171 Document Mo. 118:253177 Use of HPLC diode array detection in the detection of nitrogen-containing sycatoxins and taxonomy of their producers in Penicillium. Frisvad, J. C. (Dep. Biotechnol., Technical Univ. Demark, Lyngby, Den.). Prikl. Blokhia, Mikrobiol., 29(1), 19-26 (Russian) 1993. CODER: PENIAK. ISSM: 0555-1099.

AB TLC and RPLC were applied to analyze 4500 isolates from the subgenus Penicillium representing 45 species. Various systems for MPLC anal. of alkaloids are estd. The results of this estn. are presented together with a short report on taxonomy of the most widespread producers of alkaloids in Penicillium subgenus Penicillium.

IS 5033-03-03. Chaetoglobosin A
RL: FORM (Formation, nonpreparative)
(formation of, by Penicillium, taxonomy in relation to)

Page 25

L6 AMSWER 38 OF 180 CAPLUS COPYRIGHT 1996 ACS
1993:124851 Document No. 118:124851 Total synthesis of
(-)-alloaristoteline, (-)-serratoline, and (+)-aristotelone.
Stoermer, Doris; Heathcock, Clayton H. (Dep. Chem., Univ.
California, Berkeley, CA, 94720, USA). J. Org. Chem., S8(3), 564-8
(English) 1993. CODER: JOCEAH. ISSM: 0022-3263. OTHER SOURCES:
CASREACT 118:124851; CJACS-IMAGE; CJACS.



AB The Aristotelia alkaloids (-)-alloaristoteline (I), (-)-serratoline, and (+)-aristotelone (II, X = 0), were prepd. Thus, via the method of Stevens, (15)-(-)-.beta.-pinene and 3-indolylacetonitrile were coupled by a log(NO3)2-mediated Ritter reaction followed by redd. of the resulting laine to give (+)-makomakine (III). An intramol. Friedel-Crafts reaction delivered (+)-aristoteline, which was oxidized by reaction with oxygen and platinum. Redn. of the intermediate hydroperoxide delivered alkaloid IV. Base-catalyzed skeletal rearrangement of IV followed by redn. with LiAlH4 to obtain a mixt. of secondary alcs., II (X = H,OH). Treatment of each of these alcs. with HCl in methanol afforded (-)-I.

II 79559-56-1P, (-)-Nacomakine 14614-41-4P
RL: RCI (Reactant): SPM (Synthetic preparation): PREP (Preparation) (prepn. and intramol. Friedel-Crafts reaction of)

ARSWER 39 OF 180 CAPLUS COPYRIGHT 1996 ACS
3:124830 Document No. 118:124830 Synthesis of Aristotelia-type
alkaloids. Part XI. Total syntheses of (+)-sorelline and
(+)-aristolasene. Obbler, Markus; Beerli, Rene; Weissmahr, Walter
K.; Borschberg, Hans Juerg (Lab. Org. Chem. Eldgenoessischen Tech.
Nochsch., EIH Zentrum, Zurich, CH-8052, Switz.). Tetrahedron:
Asymmetry, 7(11), 1411-20 (English) 1992. CODEm: TASYES. ISSM:
0957-4166. OTHER SOURCES: CASREACT 118:124830.

Optically pure samples of the rare Aristotelia alkaloids (*)-sorelline (1) and (*)-aristolasene (11) were synthesized for the first time. Since natural (5)-perilla alc. served as one of the starting building blocks, these syntheses delineate the previously unknown abs. configurations of these metabolites. (-)-20-Mydroxyhobartine (111) was also prepd., which turned out to be different from a natural product that had been assigned this structure six years ago. IT 145801-31-6P

II 145801-31-6P
RI: RCI (Reactant); SPM (Synthetic preparation); PREP (Preparation) (prepn. and cyclocondensation of, with tri-Et orthoformate)
II 146234-97-1P, (-)-20-Hydroxynbobartine
RI: RCI (Reactant); SPM (Synthetic preparation); PREP (Preparation) (prepn. and oxidn. of)
II 73004-61-2P. (-)-Hobartine 145801-27-0P
145842-73-5P

RL: SPW (Synthetic preparation); PREP (Preparation) (prepn. of)
11 73004-62-3P

RL: PREP (Preparation); RCT (Reactant)

AMSWER 40 0F 180 CAPLUS COPYRIGHT 1996 ACS
3:120637 Document No. 118:120637 Blosynthetic study of
chaetoglobosin A: origins of the oxygen and hydrogen atoms, and
indirect evidence for a biological Diels-Alder reaction. Oikawa.
Hideaki; Murakami, Yasunobu; Ichihara, Akitami (Fac. Agric.,
Nckakido Univ., Sapporo, 600, Japan). J. Chem. Soc., Perkin Trans.
1 (21), 295-9 (English) 1992. CODEM: JCPRB4. ISSM: 0300-922X.
OTHER SOURCES: CJRSC.

- AB The biosynthetic origins of the 0 and H atoms in the mycotoxin chaetoglobosin A [1] were investigated by the incorporation of [1-13C,1802]- and [1-13C43]-acetate and 1802 into 1 by using the chaetoglobosin-producing strain Chaetomium subaffine. Cytochrome P 450 expts. support a biogenetic pathway from prochaetoglobosin I [11]. Attempts at direct conversion of 14C- or 13C-labeled II using whole cells were unsuccessful. Formation of the disateredisoner of II in the retro-Diels-Alder reaction of II provided indirect evidence that the plausible precursor hexame is able to cyclize via [4 · 2]cycloaddn. in the biosynthesis of I.

 11 133613-77-1, Prochaetoglobosin I
 RL: BIOL (Biological study) (chaetoglobosin A formation from, by Chaetomium subaffine.)

 11 50335-03-0, Chaetoglobosin A
 RL: FORM (formation, nonpreparative) (formation of, by Chaetomium subaffine, pathway of)

 11 145511-72-4P
 RL: SPM (Synthetic preparation); PREP (Preparation) (prepn. of)

(prepn. of)

08/466,644

Page 26

L6 ANSWER 39 OF 180 CAPLUS COPYRIGHT 1996 ACS (Continued)

```
L6 AMSWER 41 OF 180 CAPLUS COPYRIGHT 1996 ACS
1993:120537 Document Mo. 118:120537 Useful approach to find the
plausible blosynthetic precursors of secondary metabolites using
P-450 Inhibitors: postulated intermediates of chaetoplobosin A.
Olkawa, Nideaki; Murakami, Yasunobu; Ichihara, Akitami (Fac. Agric.,
Hokkaido Univ., Sapporo, DGO, Japan). J. Chem. Soc., Perkin Trans.
1 (21), 2949-53 (English) 1992. CODEM: JCPR84. ISSM: 0300-922X.
OTHER SOURCES: CJRSC.
GI
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLIKE PRINT *

AB Treatment of Chaetomium subaffine with specific cytochrome P 450 inhibitors resulted in a new generation of plausible precursors of chaetoglobosin A (1), named prochaetoglobosins I (11), 11 (111), 111 (111), 111 (111), 111 (111), 112 (111), 113 (111), 114 (111), 115 (111)

II 146426-37-1 146426-38-2

RL: FORM (Formation, nonpreparative)
(formation of, by Chaetonium subaffine)
II 50335-03-0, Chaetoglobosin A

RL: FORM (Formation, nonpreparative)
(formation of, by Chaetonium subaffine, cytochrone P 450
inhibitor effect on)
II 50645-76-6 55945-75-0, Chaetoglobosin F

RL: FORM (Formation, nonpreparative)
(formation of, by Chaetonium subaffine, metyrapone effect on)
II 33613-77-1 133613-78-2 133625-26-0
137604-97-8

137604-97-8
RL: BIOL (Biological study)
(of Chaetonium subaffine, as potential chaetoglobosin A
precursor)

L6 AMSWER 42 OF 180 CAPLUS COPYRIGHT 1996 ACS
1993:59942 Document No. 118:59942 The alkaloid peduncularine:
corrected spectroscopic data and conformational analysis. Oragar,
Charles; Bick, I. Ralph C. (Dep. Agric. Sci., Univ. Tasmania,
Robart, 7005, Australia). Phytochemistry, 31(10), 3601-3 (English)
1992. CODEM: PYTCAS. ISSN: 0031-9422.

- The reported spectroscopic data for the alkaloid peduncularine (I) from Aristotelia peduncularis have been revised and its preferred conformation has been investigated using MOE difference
- spectroscopy. IT 34964-75-5, Peduncularine 145164-88-1,

Peduncularine monohydrochloride
RL: RCT (Reactant)
{cor. spectroscopic data and conformational anal.}

- L6 AMSMER 44 OF 180 CAPLUS COPYRIGHT 1996 ACS
 1992:610477 Oocument Mo. 117:210477 Cytochalasans and PMA induce IL-2
 receptors on CO8+ lymphocytes. Grove, Deborah S.; Stanek, Elaine
 M.; Bour, Barbara A.; Mastro, Andrea M. (Dep. Mol. Cell Biol.,
 Pennsylvania State Univ., University Park, PA, 16802, USA). Exp.
 Cell Res., 202(2), 303-9 (English) 1992. CODEM: ECREAL. ISSN:
 OO14-4827.
- OO14-4827.

 A The cytochalasans, fungal metabolites that interact with actin, can affect lyaphocyte proliferation; high concns. inhibit lectin-induced proliferation and low concns. augnent it. The phorbol ester tumor promoter, PMA, alone is not altogenic for primary lyaphocytes but enhances the activity of mitogenic lectins. Because the cytochalasans have been reported to increase intracellular Ca2+ and because PMA activates protein kinase C, lyaphocytes were treated with PMA and cytochalasins B (Cy8) to det. If this combination would induce DMA synthesis. While this treatment by itself did not cause proliferation, lyaphocytes cultured with PMA and Cy8 overnight, washed, and recultured with IL-2 proliferated to the same degree as lyaphocytes stimulated with Con A. Three different cytochalasans, cytochalasin B, cytochalasin D, and chaetoglobosin C, all of which bind to cellular actin with different affinities and only one of which affects glucose transport, induced IL-2 receptors in combination with PMA. Flow cytometric anal, with an antibody to the IL-2 receptor .alpha. subunit confirmed the induction of receptors on CB8+ cells. However, no IL-2 was produced after the exposure of lyaphocytes to the combination of cytochalasans and PMA. Therefore, there was sufficient signal to induce IL-2 receptor expression but not to induce IL-2.

 Il 50645-76-6, Chaetoglobosin C
 RL: 810 (Stological study)
 (phorbol ester and, interleukin-1 receptors induction by, on CB8 lambourts subsets. The cytochalasans, fungal metabolites that interact with actin, can
- - (phorbol ester and, interleukin-1 receptors induction by, on CD8 lymphocyte subset)

08/466,644 Page 27

> L6 AMSWER 43 OF 180 CAPLUS COPYRIGHT 1996 ACS
> 1992:651128 Document No. 117:251128 Synthesis and serotonergic
> pharmacology of the enantiomers of 3-[(H-methylpyrrolidin-2yl]methyl]-5-methoxy-Hi-indole: discovery of stereogenic
> differentiation in the mainoethyl side chain of the neurotransmitter
> serotonin. Macor. John E.: Bladke, James; Fox, Carol B.; Johnson,
> Celeste; Koe, B. Kenneth; Lebel, Lorraine A.; Morrone, Jean M.;
> Ryan, Kevin; Schmidt, Anne W.; et al. (Cent. Res. Div., Pfizer,
> Inc., Groton, CT, 06340, USA). J. Med. Chen., 35(23), 4503-5
> [English] 1992. CODEN: JMCMAR, 15SM: 0022-2623. OTHER SOURCES:
> CLACS-IMMEG; CLACS-CJACS-IMAGE; CJACS.

AB The synthesis and pharmacol. of both (R)- and (S)-3-{Nnethylpyrolidin-2-ylnethyl)-5-methoxyindole (I) are presented.
Affinity for serotonergic receptors (5-HIIA, 5-HIIB, 5-HIIC, 5-HIIO,
and 5-HI2) is significantly greater for (R)-1 (CP-108,509). The
potency and efficacy of (R)-I approx. equals that of the natural
substrate serotonin at 5-HIIA, 5-HIID, 5-HIIC, and 5-HI2 receptors.
The 3-(pyrnolidin-2-ylaethyl) group in (R)-1 represents a
stereogenic, conformationally restricted mimic of the
3-(2-aninoethyl) group in serotonin at 5-HIIA, 5-HIIC, 5-HIID, and
5-HI2 receptors.
II 143121-56-69 143312-57-7P, CP-108,509
RL: SPM (Synthetic preparation); PREP (Preparation)
(prepn. and serotoninergic receptor binding by)

L6 AMSWER 45 OF 180 CAPLUS COPYRIGHT 1996 ACS
1992:571215 Document No. 117:171215 Preparation of
3-[heterocyclylmethyl] indoles as drugs. Macor, John Eugene; Wythes,
Martin James (Pfizer Inc., USA). PCT Int. Appl. wD 9205973 A1
920430, 82 pp. DESIGMATED STATES: W: AU, BG, BR, CA, CS, DE, FI,
HU, JP, KR, NO, PL, RD, SU, US; RN: AT, BE, BF, BJ, CF, CG, CH, C1,
CM, DE, DK, ES, FR, GA, GB, GR, IT, LU, ML, MR, NL, SE, SM, TD, TG,
(English). CODEN: PIXXOZ. APPLICATION: WD 91-US7194 911008. PRIORITY: US 90-597928 901015.

AB Title compds. I [n = 0-2; R2 = H, halo, cyano, R40 (wherein R4 = H, C1-6 alky1, ary1), R6R5HCO(CH2)m, R6R5HSOZ(CH2)m (wherein R5, R6 = H, C1-6 alky1, ary1, C1-3 alky1ary1, R5R5 = 4-6-membered ring), R8CONRY(CH2)m (R5R5MZ(CH2)m, Wherein R7, R6 = H, C1-6 alky1, ary1, C1-3 alky1ary1), R8(0)x5(CH2)m, R6R5HCOHRY(CH2)m, R60ZCHRY(CH2)m, R60ZCHATTACH, R60ZCHATTACH, R60ZCHATACH, R60ZCHATACH, R60ZCHATACH, R60ZCHATACH,

RI: RCT (Reactant)
(hydrogenation of, in prepn. of serotonin agonist)
IT 143122-46-7F
RI: RCT (Reactant); SPM (Synthetic preparation); PREP (Preparation)

K1: KLI (Reactant); SPM (Synthetic preparation); PREP (Preparation); PREP (Preparation); PREP (Preparation); PREP (Preparation); I 143121-9-3P 143121-8-9-6P 143121-8-18-4-0P 143121-8-18-0P 143121-8-0P 143122-01-8-0P 143122-01-8-0P 143122-01-9P 143122-07-0P 143122-0P 14312-0P 14312-0

RL: RCT (Reactant): SPN (Synthetic preparation): PREP (Preparation)

RL: RCI (Reactant); SPM (Synthetic preparation); PREP (Preparation) (prepn. and reaction of, in prepn. of serotonin agonist) II 143321-56-8P 143321-72-6P 143321-73-7P RL: RCI (Reactant); SPM (Synthetic preparation); PREP (Preparation) (prepn. and reaction of, in prepn. of serotonin agonist drug) II 5275-05-8P 101832-07-9P 143321-54-4P 143321-55-9P 143321-66-6P 143321-57-7P 143321-59-9P 143321-66-2P 143321-61-3P 143321-62-4P 143321-75-9P 143321-75-9P 143321-75-9P 143321-75-9P 143321-75-9P 143321-75-9P 143321-75-9P 143321-75-9P 143322-05-8P 143322-05-9P 143322-10-5P 143322-11-6P 143322-12-7P

```
ARSWER 45 OF 180 CAPLUS COPTRIGHT 1996 ACS
143322-13-07 143322-14-09 143322-15-07
143322-15-17 143322-17-27 143322-18-19
143322-19-17 143322-20-77 143322-21-87
143322-25-27 143322-23-07 143322-24-17
143322-25-27 143322-23-07 143322-27-47
143322-25-27 143322-35-07 143322-31-27
143322-31-07 143322-31-27 143322-31-27
143322-31-07 143322-31-27 143322-31-27
143322-31-07 143322-31-27 143322-35-65
143322-41-47 143322-35-27 143322-35-67
143322-43-47 143322-35-27 143322-35-67
143322-43-47 143322-35-27 143322-55-87
143322-35-67 143322-55-27 143322-55-87
143322-50-37 143322-51-47 143322-55-87
143322-51-47 143322-52-57 143322-55-87
143322-51-47 143322-52-57 143322-55-97
143322-51-47 143322-53-47 143322-55-97
143322-51-47 143322-53-47 143322-55-97
143322-51-47 143322-53-47 143322-55-97
143322-51-47 143322-53-47 143322-55-97
143322-51-47 143322-53-47 143322-55-97
143322-51-47 143323-63-77 143322-50-57
143322-51-47 143323-63-77 143322-50-57
143322-51-47 143323-63-77 143323-60-57
143322-51-47 143323-63-77 143323-60-57
143322-51-47 143323-63-77 143323-60-57
                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (Continued)
           143577-63-3P
                       NR: BAC (Biological activity or effector, except adverse); SPH
(Synthetic preparation); TBU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)
(prepa. of, as drug)
```

L6 AMSWER 47 OF 180 CAPLUS COPYRIGHT 1996 ACS 1992:426178 Document No. 117:26178 Synthesis and Pictet-Spengler reaction of 2-skstylpiperidine, -homopiperidine and -amino acids. Hanama, W. S.; Hammouda, M.; Kandeel, E. M.; Afsah, E. M. (Fac. Sci., Mansoura (M., Mansoura (Rgypt). Zhonghua Yaoxue Zazhi, 44(1), 25-9 (English) 1992. CODEM: CYHCEX. ISSM: 1016-1015.

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

A8 Schmidt reaction of 2-skatylcycloalkanones I (n = 1, 2) gave the corresponding cyclolactams, which were reduced to the 2-skatylpiperidine (II, n = 1) and -homopiperidine (II, n = 2) resp. Acid hydrolysis of the lactams gave skatylamino acids III (n = 3, 4). Carbolines IV and V were obtained via treatment of III and II with formalin.

II 5275-05-0P
R1: RCI (Reactant); SPM (Synthetic preparation); PREP (Preparation) (prep. and reaction of, with formaldehyde)

II 141647-09-0P
R1: RCI (Reactant); SPM (Synthetic preparation); PREP (Preparation)

RL: RCI (Reactant); SPM (Synthetic preparation); PREP (Preparation) (prepm. and redm. of)

L6 ARSWER 46 OF 180 CAPLUS COPYRIGHT 1996 ACS
1992;448167 Document No. 117:48167 The synthesis of optically pure
.beta.-cyclopiazonic acid, an indolic fungal metabolite. Holzapfel,
Cedric W.; Kruger, Friedrich W. H. (Dep. Chem. Blochem., Rand
Afrikaans Univ., Johannesburg, 2000, S. Afr.). Aust. J. Chem.,
45(1), 99-107 (English) 1992. CODEM: AJCHAS. ISSM: 0004-9425.

The chiral synthesis of the fungal metabolite .beta.-cyclopiazonic acid is described. The key step involves the use of the tricarbonylchromium complex of an X-protected L-tryptophan Me ester as a substrate for the addn./oxidn. method of substitution of its

as a substrate for the adon./oxion. actnoo or substitudole ring system.

Il 142287-59-0P

RL: SPM (Synthetic preparation); PREP (Preparation)
(prepn. of, as cyclopiazonic acid precursor)

L6 AMSWER 48 0F 180 CAPLUS COPYRIGHT 1996 ACS
1992:255027 DOCUMENT NO. 116:255027 Synthesis of cyclic ketomethylene
dipeptide derivatives. Doninguez, N. J.; Gonzalez-Muniz, R.;
Garcia-Lopez, M. I. (Inst. Quin. Med., Nadrid, 28006, Spain).
1etrahedron, 46(13), 2761-72 (English) 1992. CODEM: TETRAB. ISSM:
0040-4020. OTHER SOURCES: CASREACT 116:256027.

AB Me 6-aralkyl-2,5-diketopiperidine-3-carboxylates I (R = Ph, 3-indolyl; Rl = M) derived from L-Phe and L-Trp, and their 3-substituted analogs I (R = Ph, 3-indolyl; Rl = CHZPh, COZCOZEt, Me) in which the 3-substituent is the side chain of Phe, Asp, and Ala have been synthesized. Cyclo[Trp,psi.(COCHZ)cly] (II; R = 3-indolyl, Rl = M) and cyclo[Phe.psi.(COCHZ)-.xi.-Phe] (II; R = Ph, Rl = CHZPh) have been also prepd.

II 135941-69-4 135941-72-9
RL: RCI (Reactant) (deprotonation-alkylation reactions or sapon. of)

II 141672-21-IP 141672-24-49
RL: RCI (Reactant): SPM (Synthetic preparation); PREP (Preparation) (prepn. and decarboxylation of)
II 136959-62-59 136959-31-69 136959-63-9P
115959-67-OP 136969-70-5P 136969-71-6P
135969-71-8P
RL: SDM (Synthetic preparation); PREP (Preparation)

RL: SPW (Synthetic preparation); PREP (Preparation)

08/466,644

Page 29

L6 ANSWER 49 OF 180 CAPLUS COPYRIGHT 1996 ACS
1992:235273 Document No. 116:235273 Contribution of synthetic chemistry for new bioscience. Possibility of biological Diels-Alder reaction. Ichihara, Akttaal (Fac. Agric., Hokkaldo Univ., Sapporo, 060, Japan). Tuki Goset Kagaku Kyokaishi, 50(2), 96-111 (Japanese) 1992. CODEN TEKERE. ISSN: 0037-9980.

AB A review with 33 refs. on biosynthesis and chea. synthesis of solonapyrones, diplodiatoxin, betaenones, and chaetoglobosin A to study the possibility of biol. Diels-Alder reactions.

Il S035-03-09. Chaetoglobosin A
RL: PREP (Preparation)
(biol. and chea. synthesis of, study of Diels-Alder reaction in)

L6 ARSVER 50 OF 180 CAPLUS COPYRIGHT 1996 ACS 1992:59342 Document No. 116:59142 Chemistry of indoles carrying basic functions. I. Transformation of hydroxyindolones into indoles. Moldwai, Istwan; Gacs-Baitz, Eszter; Szantay, Csaba (Cent. Res. Inst. Chem., Hung. Acad. Sci., Budapest, N-1525, Hung.). Recl. Trav. Chim. Pays-Bas, 110(11), 437-40 (English) 1991. CODEN: RICPAJ. ISSN: 0165-0513.

R 03 1 11 11 11 111

AB 3-Hydroxy-3-(pyridylaethyl)indolones ! (R = 2-, 4-pyridyl) have been reduced with NaBH4/MeOH/tert-BuOH. After acidic treatment, 2- and 3-substituted indoles !! and !!! were obtained. The intermediates of the rearrangement were isolated and the effect of the pyridylaethyl groups on the rearrangement has also been established. IT 5580-44-9P RL: SPM (synthetic preparation); PREP (Preparation) (prepn. of)

21 SEA FILE=CAPLUS L6 AND (SHT) OR 5(1W)HT) OR MIGRAME/ OR H EADACKE/ OR VASODILATOR/ OR HYPERTENSION OR ANTIHYPERTENS IVE OR VASOCONSTRICTOR OR RAYMOND?)/AB,BI

=> d 1-21 cbib abs hitrn

08/466,644

Page 31

17 ARSWER 1 OF 21 CAPLUS COPYRIGHT 1996 ACS
1995:987946 Preparation of {(triazoly)}indoly]aethylpyrrolidines as
5-HT1-like agonists. Matassa, Yictor Guilio;
Sternfeld, Francine; Street, Leslie Joseph (Merck Sharp and Dohne
tud., UK). PCT Int. Appl. NO 9921167 A1 950810, 27 pp. 0E516MATED
SIATES: W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CH, CT, DE, DK, EE,
ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, ND,
NG, NM, NM, KX, KL, NO, NZ, PL, PI, RO, RU, SD, SE, SI, SK, TJ, TT,
UA, US; RD: AT, BE, BF, BJ, CF, CB, CH, CI, CM, DE, DK, ES, FR, GA,
GB, CR, EL, II, LU, NF, NL, NR, HE, NL, PT, SE, SN, TD, FG.
(English). CDEM: PIXXUZ. APPL(CATION: WO 95-GB135 950124.
PRIDRITY: GB 94-2011 94020Z.
AB Title compds. {[: R * H, Cl-6 alky]}, were prepd. Thus,
4*-[1,2,4*-triazol-4-y])phenylnydrazine and [25]-N-tertbuttoxycarbonyl-3-{Dyrrolidin-2-yl]propanal were stirred in 4% aq.
NZSO4 at room temp.-reflux to give 14% I (R * H), isolated as the
oxalate. I showed pECSO .gioreq.5.0 in a test of their ability to
mediate contraction of the saphenous vein of rabbits.

IR R LIST MY NOT BE COMPLETE: 15854-16-8
171550-18-4
171550-18-5
171550-18-6

L7 AMSWER 2 OF 21 CAPLUS COPYRIGHT 1996 ACS (Continued) (prepn. of triazole derivs, as serotoninergic agonists)

(Prepn. of triazole derivs. as acrossmining a symmetry, [T 171182-24]
RL: RCT (Reactant); SPM (Synthetic preparation); PREP (Preparation) (prepn. of triazole derivs. as serotoninergic agonists)

ARSWER Z OF 21 CAPLUS COPYRIGHT 1996 ACS
1:959448 Document No. 124:8823 Preparation of triazole derivatives
as serotoninergic agonists. Matassa, Victor Giulio; Sternfeld,
Francine; Street, Leslie Joseph (Merck Sharp and Dohme Ltd., UK),
PCI Int. Appl. NO 9521166 A1 950810, 49 pp. DESIGNATED STATES: W:
AM, AT, AU, BB, BG, BR, BY, CA, CH, CH, CZ, DE, DX, EE, ES, FI, GG,
EE, RU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, YM, DM, KM, MM,
MX, MI, NO, NZ, PI, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US; RX:
AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE,
IT, LU, MC, ML, MR, KE, ML, PT, SE, SM, TD, TD. (English) CODEM:
PIXXIZ. APPLICATION: NO 95-GB134 950124. PRIORITY: GB 94-2016
940202.

AB Title compds. [1; R = H, hydrocarbyl, heterocyclyl, etc.; R1 = cycloalkyl, alkozyalkyl, aryl(alkyl), etc.; 1 of Y,Z = N and the other = (un)substituted (H; Z1 = bond, alkylene; Z2 = 0, S, (alkyl)larino; Z3 = N, (alkyl-substituted)(H; Z4 = alkylene; p = 0 or 1; q = 1-4; prq = 2-4], agonists of 5-HT1-like receptors, were prepol. Thus, (ZR)-A-tert-butoxycarbonylpyrrolidine-2-propanal was cyclocondensed with 4-(1,Z,4-triazol-4-yl)phenylhydrazine (prepn. each given) and the product condensed with Pht0h to give title compd. II. I had pECSO of .gtoreq.5.0 for contraction of rabbit saphenous vein.

If J7182-20-0P J7182-21-1P J7182-22-2P
J7182-23-3P J7182-24-4P J7182-25-5P
J7182-26-6P J7182-20-2P J7182-28-8P
J7182-29-9P J7182-30-2P J7182-31-3P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

17 ANSWER 3 OF 21 CAPLUS COPYRIGHT 1996 ACS
1995:933846 Document No. 124:688 The in vivo pharmacological profile
of a S-HTI receptor agonist, CP-122,288, a
selective inhibitor of neurogenic inflammation. Gupta, P.; Brown,
D.; Butler, P.; Ellis, P.; Grayson, K. L.; Land, G. C.; Macor, J.
E.; Robson, S. F.; Wythes, M. J.; Shepperson, K. B. (Departaents of
Discovery Biology and Discovery Chemistry, Pfizer Central Research,
Sandwich, Kent, Cli3 SMJ, UK). Br. J. Pharmacol., 116(5), 2385-90
(English) 1995. CODEN: BJPCBM. ISSN: 0007-1188.
AB The ain of the present study was to investigate the in vivo
pharmacol. profile of CP-122,288, an indole-deriv. with a
conformationally restricted N-methylpyrrolidinyl basic side chain in
the C-3 position. This C-3 substituent structurally differentiates
CP-122,288 from the S-Hill receptor agonist sumatriptan, which
possesses an N,M-dinethylaninochyl group. When administered prior
to elec. stimulation of the trigential ganglion, CP-122,288 (0.3-200
ng kg-1, i.v.) produced a dose-related inhibition of plasma
retravasation in rat dura mater (min. ED, MED, 3 ng kg-1 i.v., P <
0.05; maximal inhibition of plasma extravasation at 30 ng kg-1 i.v., P <
0.05; maximal inhibition of plasma
leakage in the dura, but a much higher dose levels (MED, 100 .nu. g
kg-1 i.v., P < 0.05). Thus, CP-122,288 is of the order of 104 fold
more potent than sumatriptan. At all doses tested, CP-122,288 did
not inhibit plasma protein extravasation measured in extravantal
tissues such as the lower lip, eyelid, and conjunctiva. In a sep.
series of studies in the anesthetized rat, CP-122,288 (0.00-33 .nu.)
kg-1 i.v.) produced no change in either heart rate or mean arterial
blood pressure, thus demonstrating that doses of CP-122,288 doi
not inhibit plasma protein leakage in rat dura, are devoid of
hemodynanic effects. Following a 5 min period of sustained
neurogenically-driven plasma extravasation, occurring in the absence
of elec. stimulation, was initiated. By administration of the
compd. 5 min after completing the

IT 14332-74-0, CP-122288
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); TRU (Therapeutic use); BIOL

AKSWER 3 OF 21 CAPLUS COPYRIGHT 1996 ACS (Continued)
(Biological study); USES (Uses)
(CP-122,288 pharmacol. profile as selective inhibitor of neurogenic inflammation in relation to migraine treatment) L7

```
7 AASWER 4 OF 21 CAPLUS COPYRIGHT 1996 ACS (Continued)
167302-93-4P 167302-94-5P 167302-95-6P
167302-95-7P 167302-97-8P 167302-99-9P
167303-99-0P 167303-00-6P 167303-04-0P
167303-05-1P 167303-06-2P 167303-04-0P
167303-05-1P 167303-06-2P 167303-07-3P
167303-05-1P 167303-06-2P 167303-07-3P
167303-11-9P 167303-12-0P 167303-13-1P
167303-12-9P 167303-12-0P 167303-13-1P
167303-12-9P 167303-12-1P 167303-12-3P
167303-12-9P 167303-12-1P 167303-12-3P
167303-12-9P 167303-12-1P 167303-12-3P
167303-12-1P 167303-12-1P 167303-12-3P
167303-12-1P 167303-12-1P 167303-12-9P
167303-12-1P 16
```

08/466,644 Page 32

L7 AMSMER 4 OF 21 CAPLUS COPYRIGHT 1996 ACS
1995;72570 DOCUMENT NO. 123:169499 Indole derivatives as 5HTI-11te agonists for use in migraine. Mythes, Martin James
(Pfizer Ltd., UK; Pfizer Inc.; Pfizer Research and Development
Company, N. V. S.A.). PCT Int. Appl. NO 9424127 AI 941027, 124 pp.
DESIGNATHOE STATES: N. AU, BR, CA, CH, CZ, FI, HU, JP, KR, NO, RZ,
PL, RU, US; RN: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC,
KL, PT, SE. (English). CODEAR PIXXOZ. APPLICATION: NO 94-EP1121
940411. PRIORITY: GB 93-8360 930422; GB 93-24433 931127. A8 The title compds., 3-(pyrrolidinylmethyl)indoles and 3-(piperidinylmethyl)indoles i [R] = (2-pyrrolidinyl)methyl, 3-pyrrolidinyl, 4-piperidinyl, (3-piperidinyl)methyl; R2 = alkyl, oxoalkyl, etc.] were disclosed as selective 5-KHI - like agonists useful in the treatment of migraine, cluster headache, chronic paroxysnal hemicrania and headache assocd. with vascular disorders. A specifically claimed example compd. is 5-(3-hydroxybutyl)-3-[(R)-(1-methyl-2-pyrrolidinyl)methyl]-1-H-indole (II).

II 14332-57-0
RL: RCT (Rectant)
(prepn. of (pyrrolidinylmethyl)indoles 5-HTI RI: RCT (Reactant) (prepn. of (pyrrolldinylnethyl)indoles S-HTI -11ke agonists) IT 14322-46-7P 153435-71-3P 153435-73-5P 153525-35-0P 153525-50-9P 153525-51-0P 167303-50-6P 167303-51-7P 167303-54-0P 167303-51-3P 167303-56-2P 167303-63-1P 167303-64-2P 167303-66-4P 167303-67-5P

L7 AMSWER 5 OF 21 CAPLUS COPYRIGHT 1996 ACS
1995:349880 Document No. 122:306133 Effect of a 5HTI receptor agonist, CP-122,288, on edema formation induced
by stimulation of the rat saphenous nerve. Kajekar, Radhika; Gupta,
Paul; Shepperson, Nicholas B.; Brain, Susan D. (Vascular Biology
Research Centre, King's College, London, SW3 6LX, UK). Br. J.
Pharmacol., 115(1), 1-2 (English) 1995. CODEN: BJPCBM. ISSN:
0007-1188.

Pharmacol., 115(1), 1-2 (English) 1995. CODEN: BJPCDM. ISSN: DOO7-1186.

AB Neurogenic edema formation in the rat hind paw skin induced by elec. stimulation of the saphenous nerve and measured by extrawasation of [1251]-albumin, was inhibited by the 5-HIIB receptor agonist, CP-93,129, and the novel tryptamine analog, CP-122,288. Significant inhibition of up to 66% of control was obsd. with CP-122,2788 (2 .times. 10-7 no) kg-1) and CP-93,129 [5 .times. 10-6 no) kg-1), with the min. ED for CP-122,288 being about 107 fold less than that for GP-93,129. Edema formation induced by the intradermal administration of exogenous mediators (substance P and histamine) in rat dorsal skin was not inhibited by CP-122,288 (2 .times. 10-10 mol kg-1). These results suggest that CP-122,288 is a potent inhibitor of neurogenic inflammation in rat skin and that the effect may be due to a prejunctional inhibition of neuropeptide release.

II 143321-74-8, CP-122288

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (neurogenic edema inhibition by 5-HTI receptor agonist CP-122288)

- ANSWER 6 OF 21 CAPLUS COPYRIGHT 1996 ACS
- AASWER 6 GF 21 CAPLUS COPYRIGHT 1996 ACS
 95:466381 Document No. 1272:756183 The pre- and postjunctional
 activity of CP-1272,268, a conformationally restricted analog of
 sumatriptan. Beattie, David I.; Connor, Helen E. (Pharmacology II,
 Glaxo Research and Development Ltd., Park Road, Ware Herts, SG12
 ODP, UK). Eur. J. Pharmacol., 276(3), 271-6 (English) 1995. CODEN:
 EUPHAZ. ISSN: ODI-27999.

 The present study investigated the pre- and postjunctional activity
 of CP-122,288 (S-methyl-aninosulfonylmethyl-3-(K-methylpyrrolidin-2Ryl-methyl)-1H -indole), an analog of the vascular SHTI receptor agonist, sumatriptan. CP-122,288 inhibited
 neurogenic plasma protein extravasation in rat dura with a potency
 approx. 40 000-fold greater than sumatriptan (ISO values of O.3
 pool/kg and 13-9 nool/kg i.v. resp.). However, CP-122,288 was only
 approx. 2-fold more potent than sumatriptan at inhibiting
 neurogenically mediated contractions of the dog saphenous vein.
 CP-122,288 contracted the dog saphenous vein and basilar artery with
 a potency approx. 2-fold greater than that of sumatriptan. Both
 compds. possessed similar affinites at either human S-HID. alpha.
 or S-HID. beta. receptors. It is concluded that CP-122,288 exhibits
 a prejunctional selectivity in the meninges to inhibit dural plasma
 protein extravasation independent of S-HID.alpha. and S-HID.beta.
 receptor activation.

protein extravasation independent of 5-HT10.alpha. and 5-HT10.be receptor activation. II 143921-74-8, CP-122288 Ri: BAC (Biological activity or effector, except adverse); BIOL (Biological study) (pre- and postjunctional activity of CP-122,288, a conformationally restricted analog of sumatriptan)

- AMSWER 8 OF 21 CAPLUS COPYRIGHT 1996 ACS
 :354225 DOCUMENT NO. 122:133200 5-arylindole derivatives and their
 use as serotonin (5-HT1) agonists. Macor., John
 Eugene (Prizer Inc., USA). PCT Int. Appl. W0 9410171 A1 940511, 72
 pp. DESIGNATED SIATES: W: AU, BR, CA, CZ, JP, KR, KO, KZ, PL, RU,
 US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT,
 SE. (English). CODEN: PIXXOZ. APPLICATION: W0 93-US9790 931019.
 PRIORITY: US 92-970758 921102.
- A8 The title compds. I (R1 = aninoalkyl; R2-R5 = N, alkyl, aryl, etc.) were disclosed. I are useful in treating migraine and other disorders; they are useful psychotherapeutics and are potent serotonin (5-HT) agonists and herzodiazepine agonists and antagonists and benzodiazepine agonists and antagonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, nigraine, pain and chronic paroxysmal hericrania and headache assocd. With vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. I are also useful as centrally acting antihypertensives and vasodilators. A specifically claimed example compd. is 5-cyano-1-[[3-[1-2-acthoxyethyl)-2-pyrrolidinyl]methyl]-5-indolyl]-11-benzimidazole [il]. II 160907-00-P 160907-05-IP 160907-06-2P 160907-07-3P RL: SPM (Synthetic preparation); PREP (Preparation)

160907-08-4P

(prep. of)

[11 43922-01-4P 151272-89-8P 151272-90-1P

151272-99-0P 151273-06-8P 151273-01-7P

151273-05-1P 151273-05-2P 151273-07-3P

151273-05-4P 151273-11-9P 158752-53-5P

160906-47-8P 160906-48-9P 160906-46-7P 160906-47-8P 160908-48-9P 160906-49-1P 160906-50-3P 160906-51-P 160906-54-7P 160906-55-8P 160906-81-0P 160906-82-1P 160906-83-2P 160908-84-3P 160906-83-4P 160906-83-3P 160908-97-8P 160906-95-6P 160906-96-7P 160908-97-8P 160907-00-6P

17 ARSWER 7 OF 21 CAPLUS COPYRIGHT 1996 ACS
1995:421524 Document No. 122:205025 Suppression by the sumatriptan analog, CP-122,288 of c-fos immunoreactivity in trigestinal nucleus caudalis induced by intracistermal capsaicin. Cutrer, F. Michael; Schoenfeld, David; Limmoth, Volker; Panahian, Mariman; Moskowitz, Michael A. (Harvard Med. Sch., Massachusetts Gen. Hosp., Boston, MA, 02114, USA). Br. J. Pharmacol., 114(5), 987-92 (English) 1995.
CODER: BUPCBM, ISSR: 0007-1188.

All he effects of an iv. administered sumatriptan analog were exand. on c-fos-like immunoreactivity (c-fos-tl.), a marker of neuronal activation, evoked within trigenian nucleus caudalis (IKC) and other brain stem regions 2 h after intracisternal injection of the irritant, capsaicin (0.1 mg. 0.1 mM), in pentobarbitone-anesthetized Hartley guinea pigs. C-fos-tl was assessed in eighteen serial sections (50 mm. a) using a polyclonal antiserum. A weighted av., reflecting total expression within laxina i, 110 of IRC was obtained from three representative levels (i.e., at -0.225 mm. -2.475 mm and -6.075 mm). Capsaicin caused significant labeling within laxina i, 110, a region contg. axonal terminatins of small unmyelinated C-fibers, as well as within the nucleus of the solitary tract, area postrema and medial reticular nucleus of the solitary tract, area postrema and medial reticular nucleus of the solitary tract, area postrema and medial reticular nucleus. A similar distribution of other chem. Irritants such as autologous blood or carrageenin. Pretreatment with a conformationally restricted sumatriptan analog (with some selectivity for 5-M18 and 5-M170 receptor subtypes) CP-122,288, reduced the weighted av. by approx. 50-60x (P < 0.05) in laxina 1, 110 ax 100 pool kg-1, i.v., but did not decrease cell no. within area postrema, nucleus of the solitary tract or medical reticular nucleus. A similar pattern was reported previously following sumatriptan, dihydroergotantne or CP-93,128 administration after noxious meningeal stimulation. We conclude that a

AMSMER 8 OF 21 CAPLUS COPYRIGHT 1996 ACS (Continued)
RL: SPM (Synthetic preparation); PREP (Preparation)
(preph. of, as intermediate for arylindole serotoninergic
agonist) 160907-03-99 160907-03-9P
RL: SPM (Synthetic preparation); PREP (Preparation)
(prepn. of, as serotoninergic agonist)
II 151272-88-7
RL: RCT (Reactant)
(reactant for arylindole serotoninergic agonist) IT 160907-09-5
RL: RCT (Reactant)
(serotoninergic agonist)

AMSVER 9 OF 21 CAPLUS COPYRIGHT 1996 ACS
95:300051 Document No. 122:64328 Use of indole derivatives as
5-HTI antagonists. Macor, John Eugene (Pfizer
Inc., USA). PCI int. Appl. NO 942502 31 941110, 22 pp. DESIGNATED
STATES: W: AU, BG, BR, CA, CH, CZ, FI, HU, JP, KR, ND, NZ, PL, ND,
KU, SK; NS: AT, BE, BF, BJ, CF, CG, CH, CI, CH, OG, DK, ES, FR, GA,
GB, GR, IE, IT, LU, MC, NL, MR, ME, NL, PT, SE, SM, TD, TG,
[English]. CODEN: PIXXOZ. APPLICATION: NO 94-1879 940426.
PRIORITY: US 93-53930 30047.
The present invention relates to pharmaceutical compns. contg.
(R)-5-(aethylazinosul fonylaethyl)-3-(fl-methylpyrrolldin-2-ylaethyl)IN-Indole or (R)-5-(aethylazinosul fonylaethyl)-3-(pyrrolldin-2-ylaethyl)IN-Indole or the treature of conditions such as
hypertension, depression, anxiety, eating disorders,
obesity, drug abuse, cluster headache, algraine, pain,
chronic parxyssal heaticrania, and beadache associd with

opesity, organize, cluster needsche, algraine, pain, chronic paroxyssal heatscrania, and headsche assocd. with vascular disorders.
I 183121-82-8P
Ri: RCI (Reactant); SPN (Synthetic preparation); PREP (Preparation) (1800) defervs, for treatment of disorders from deficient serotonergic neurotransaission)

IT 141121-74-8P 141121-78-2P

13221-14-0F (143221-10-2F RE: SPM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (Indole derivs. for treatment of disorders from deficient serotonergic neurotransmission)

L7 AMSWER 1) OF 21 CAPLUS COPYRIGHT 1996 ACS
1994-657330 Document No. 121:57330 Preparation of indole derivatives
as 5-HT1-11ke agonists. Macor, John Eugene;
Wythes, Martin James (Prizer Ltd., UK; Prizer Inc.; Prizer Research
and Development Co., N.Y./S.A.). PCI Int. Appl. W0 9321177 A1
931028, 70 pp. DESIGNATED STATES: W: AU, BR, CA, CZ, FI, RU, JP,
KR, NO, NZ, PL, RU, SK, UA, US; RW: AT, BE, CH, DE, DK, ES, FR, GB,
GR, IE, 1T, LU, MC, MI, PT, SE. (English). COOREM PIXXOZ
61

CH2.-- (CH2) k

Ittle compds. I [R] = (C1-6 acyl)-C1-3 alkylene, (C1-6 alkyl-O2C)-C1-3 alkylene, (M2NOC)-C1-3 alkylene, (M2NOC)-C1-3 alkylene, (M2NOC)-C1-3 alkylene, (M2NOC)-C1-3 alkylene, (M2NOC)-C1-3 alkylene, (M2) C2-7 cycloalkyll, {aryl} (3-6 alkenyl, heteroaryl-C1-3 alkylene etc.; R2 = M, halo, F3C, KR, LEMOC, M9, etc.; k = 0-2] or a salt thereof, are prepd. 5-(2-cthylsulfonylethyl)-3-(2R-pyrrodinylaethyl)-H1-hodle (prepn. given) was reacted with 2-pyridylaethyl chloride to give I (R] = 2-pyridylaethyl, R2 = 2-ESOCCHECH2, k = 1). A similar prepd. I (R1 = EUCOCH2, R2 = EUSOCCHECH2, k = 1). A similar prepd. I (R1 = EUCOCH2, R2 = EUSOCCHECH2, k = 1) evaluated for max. contraction on saphenous vein strip showed an ECSO = 3.1 . times. 10-3M. 18322-48-9 F 153452-1-3 F 153525-54-3P 153525-53-2P 153525-54-3P

153525-S5-4P

R1: SPR (Synthetic preparation); PREP (prepn. of)
11 15345-72-49 15345-73-59 153525-10-19
15345-72-49 15345-73-59 153525-10-19
153525-11-29 153525-16-99 153525-16-79
153525-07-39 153525-16-99 153525-10-09
153525-07-39 153525-12-49 153525-25-89
153525-22-69 153525-27-09 153525-25-10-9
153525-22-79 153525-31-59 153525-31-09
153525-32-79 153525-31-69 153525-31-09
153525-32-79 153525-31-69 153525-31-09
153525-31-69 153525-31-99 153525-31-09
153525-31-69 153525-31-09 153525-31-09
153525-31-69 153525-31-09 153525-31-09
153525-31-69 153525-31-09 153525-31-09
153525-47-81 153525-31-09 153525-31-09
153525-47-81 153525-48-91 153525-40-79
153525-47-81 153525-48-91 153525-40-79
153525-44-19 153525-45-91 153525-40-79
153525-44-19 153525-45-91 153525-40-91 153525-50-9P

RL: SPM (Synthetic preparation); PREP (Preparation) (prepn. of, as SHT1 agonist)

ANSWER 10 OF 21 CAPLUS COPYRIGHT 1996 ACS LI ANNER II OF 21 CAPLUS COPPRIGHT 1998 ACS
1994-483048 Document No. 121:83048 [Acylaano) indole derivatives as
5-HTL agonists. Nacor, John E. (Pfizer Inc.,
USA). PCI Int. Appl. NO 9321180 A1 931028, 32 pp. DESIGNATED
STATES: W: AU, BR, CA, CZ, DE, JP, KR, NO, KZ, PL, KU, SK, UA, US,
RY: A1, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, KL, PT, SE.
(English). CODEN: PIXOZ2. APPLICATION: NO 93-US1807 930304.
PRIORITY: US 92-866382 920410.

AB The title compds. 1 [RI = H, CI-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, (un)substituted aryl, etc.; RZ = CF3, CI-6 alkyl, aryl, CI-3 alkylaryl, etc.; RS = H, OH, alkoxy, aryloxy, acylamino, etc.; W, Y = amino acid residue; m = 0, 1; n = 0-2], which are 5-HT1 agonists (no data), useful in the treatment of hypertension (no data), useful in the treatment of hypertension (no data), etc., are prepd. Thus, M-benzyloxycabonylglycine was coupled with 5-amino-3-(M-acthylpyrrolidin-2R-ylamthyl-1H-indole, producing 5-(M-benzyloxycarbonylglycyl)amino-3-(M-methylpyrrolidin-2R-ylamthyl)-1H-indole in 74k yleld.

11 143321-58-8 143322-01-4 151272-89-8 154038-83-2 154038-83-3 154038-85-4

154038-86-5 RL: RCT (Reactant) (prepn. as serotoninergic receptor agonist)
IT 143321-58-8 143322-01-4 151273-38-0
RL: RCT (Reactant)

(reactant, in prepn. of (acylamino)indole serotoninergic receptor agonists)

L7 ANSWER 12 OF 21 CAPLUS COPYRIGHT 1996 ACS
1994:298634 Document No. 120:298634 Preparation of inidazole,
triazole, and tetrazole derivatives as 5-HTI
-11ke receptor agonists. Castro Pinetro, Jose Luis; Castro, Pineiro
Jose Luis; Guiblin, Alexander Richard; Matassa, Victor Giulio;
Reeve, Austin John; Sternfeld, Francine; Street, Leslie Joseph
(Merck Sharp and Dohne Ltd., UK). PCT Int. Appl. NO 9402477 A1
940203, 83 pp. DESIGNATED STATES: W: AU, CA, JP, US; RW: AT, BE,
CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English).
CODER: PIXXOZ. APPLICATION: NO 93-GB1495 930715. PRIORITY: GB
92-15721 920724; GB 92-25657 921208.

Title compds. [I; the broken circle represents two non-adjacent double bonds in any position in the five-membered ring; Al = H, hydrocarbyl, heterocyclyl, halo, etc.; AZ = groups cited for Al, etc.; E = bond, alkylene; R = heteroaryl group (B = 0, 5, NRS; Rl = Z-pyrrolidinothyl, 3-aninocyclobutyl, 3-pyrrolidinylmethyl, etc.; U = M, CRZ, BZ, BZ = H, alkyl; Z-4 of V, M, X, Y, Z = M and the other(s) = C [sit]] were prepd. Thus, 1-(4-hydrazinophenyl)methyl-1,Z,4-trizole and 4-(1-azetidinyl)butanal di-Me acetal (prepn. each given) were subjected to Fischer indole synthesis conditions to give title compd. II. I had pECSO of .gtoreq.5.0 for mediation of rabbit saphenous vein contraction. saphenous vein contraction. IT 154748-38-6P

154R04-04-3P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as 5-HT1-like receptor agonist)

L7 ANSWER 13 OF 21 CAPLUS COPYRIGHT 1996 ACS
1994:217271 DOCUMENT NO. 120:217273 Indole derivatives as 5HT1 agonists. Brown, Alan Daniel; Dickinson, Roger Peter;
Wythes, Martin James (Pfizer Lud., UK; Pfizer Inc.; Pfizer Research
and Development Co., N.V./S.A.). PCI Int. Appl. NO 9321178 A1
931028, 146 pp. DESIGNATED SIATES: N: AU, BR, CA, CZ, Fi, HU, JP,
KR, NO, NZ, PH, RU, SK, UA, US; RN: AT, BE, CH, DE, DK, ES, FR, GB,
GR, IE, II, LU, NC, RU, PT, SE. (English). CODER: PIXXOZ.
APPLICATION: NO 93-EP867 930408. PRIORITY: GB 92-8161 920414.

The title compos. I [R = (un)substituted Ph, pyridinyl, pyridazinyl, pyrialdinyl, pyrazinyl, furyl, thienyl; Rl = H, Cl-6 alkyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, C3-6 alkenyl, C3-6 alkynyl, etc.; α = 1, 2], which are selective agonists at the 5-HTI -like subtype of the 5-hydroxytryptasine receptor, are prepd. Thus, I [R = 3-C6HSGZMRZ, B = Me, α = 1] was prepd. and demonstrated 50% max, contraction of dog-isolated saphenous vein strip at 3.78 X 10-9 M.

nax. contraction of dog-isolated saphel M.

11 IS343-62-9 IS343-63-0 IS343-64-1 IS343-62-2 IS343-66-3 IS343-66-4 IS343-65-2 IS343-66-3 IS343-67-4 IS343-68-5 IS343-69-6 IS343-70-9 IS343-71-0 IS343-72-1 IS343-73-2 IS343-73-1 IS343-73

L7 AMSWER 14 OF 21 CAPLUS COPYRIGHT 1995 ACS
1994:106995 Document No. 120:106995 Preparation of azole indole
derivatives as 5-MTL agonists. Macor, John E.;
Novakowski, Jolanta T. (Pfizer inc., USA). PCT Int. Appl. NO
9318032 A1 930916, 38 pp. DESIGNATED STATES: W: AU, BR, CA, CZ,
DE, JP, KR, NO, NZ, PL, RU, SK, UA, US, RN: AT, BE, CH, DE, DK, ES,
FR, GB, GR, FE, TI, UJ, MC, NL, PT, SE. (English). CODEN: PIXXOZ.
APPLICATION: NO 93-US1667 930303. PRIORITY: US 92-846640 920305.

B Title compds. I (A = bond, C1-4 alky1, C1-4 alkeny1; n = O-Z; R1 = M, C1-6 alklary1, ary1, C1-3 alky1heteroary1, R6(CHZ)a wherein R6 = MC, F3C, etc., n = 1-3; w, X, Y, Z = 0, S. M, C such that at least one of M, X, Y, Z is M; K2, R3, R4, R5 = H, O1-6 alky1, ary1, C1-3 alky1ary1, C1-3 alky1heteroary1, halo, MC, F3C, OZN, etc.; one of R2B3, RR4, R6R5 = 5-7-enebhered alky1 ring, 6-membered alky1 ring, 5-7-membered heteroalky1 having 1 of O, M, S, etc.; R11 = H, R12O, R12OHM wherein R12 = C1-6 alky1, ary1, C1-3 alky1ary1) an a salt thereof useful as 5-H1, agonists (no data) and in disorders arising from deficient serotoninergic neurotransmission (no data), are prepd. (R)-1 (A = bond, n = 1, R1 = PhCH2OZC, W = S, Z = M, X = Y = C, R2 = R3 = R11 = H, R4 = PhCH2) (prepn. given) in THF was treated with Linlih to give (R)-1 (A = bond, n = 1, R1 = Me, W = S, Z = M, X = Y = C, R2 = R3 = R11 = H, R4 = PhCH2).

TS1826-19-19-152362-20-49-152362-21-5P
R1: RCT (Reactant): SPM (Synthetic preparation): PREP (Preparation) (prepn. and reaction of, in prepn. of S-HT1 agonist)

igon1st)

agomist)
IT 152162-15-PF 152362-16-8P 152362-17-9P
152362-18-0P 152362-32-8P 152362-33-9P
RL: SPM (Synthetic preparation); PREP (Preparation)
(prepn. of, as 5-HTL agomist)

08/466,644 Page 35

> L7 AKSWER 13 OF 21 CAPLUS COPYRIGHT 1996 ACS 153435-58-6 153435-71-3 153435-72-4 153435-73-5 (Continued) RL: RCT (Reactant) (prepn. as intermediate in prepn. of 5-HTL receptor agonists)

L7 ARSWER 15 OF 21 CAPLUS COPYRIGHT 1996 ACS
1994:106761 Document No. 120:106761 Indole derivatives as serotonin
receptor (5-MT1) agonists. Macor, John E.;
Wythes, Martin J. (Pfizer Inc., USA). PCT Int. Appl. MO 9320073 A1
931014, 43 pp. DESIGNATED STATES: M: AU, BR, CA, CZ, DE, JP, KR,
NO, NZ, PL, RU, SK, UA, US; RM: AT, BE, CH, DE, DK, ES, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE. (English). CODE: PIXXOZ.
APPLICATION: MO 93-US1967 930310. PRIORITY: US 92-864737 920407.

Three members of claimed indoles I [n = 0-2; m = 0-3; W = 7 types of oxo- and/or thioxo-substituted azolidinyl radicals (pyrrolidinyl, inidazolidinyl, oxazolidinyl, thiazolidinyl) with optional addnl. substitutents; Rl = N, (hydroxy)altyl, alkenyl, alkynyl, aryl, alkylaryl (sic, e.g., Cizph), alkyheteroaryl, certain heterofunctional-terminated alkyl; R2 = N, 083, NHCOR3; R3 = H, alkyl, aryl, alkylaryl), potent 5-MT agonists [no data], were prepd. for treatment of hypertension, depression, anxiety, obesity, migraine, etc. For example, Mitsunobu coupling of the alc. (R)-1-(N-benzyloxycarbonylpyrrolidin-2-yl)-3-hydroxypropene with 2-bromo-4-(2-oxo-1,3-oxazolidin-4(5)-ylmethyl)-1ctrifluoroacctylaminolpenene at the anide N (100%) xield), followed by Pd (10Ac)2-catalyzed cyclization to an indole (40%), hydrogenolytic deprotection (89%), and N-alkylation with MeOCHZCHZBr (36%), gave title compd. 11. title compd. II. IT 143322-57-0P

TI 18322-37-UP
RL: SPM (Synthetic preparation); PREP (Preparation)
[Pd-catalyzed coupling; prepn. of indole derivs. as 5HT1 agonists)
IT 182105-14-1P 182105-19-6P 182305-20-9P

Il 152305-14-IP 152305-19-6P 152305-20-9P 152305-21-0P 152305-24-1P 152305-25-4P RL: SPM (Synthetic preparation); PREP (Preparation) (intermediate; prepn. of indole derivs. as 5-HI agonists)
II 152305-12-9P 152305-13-0P 152305-22-IP

152305-26-5P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of indole derivs. as S-HTL agonists)

- 17 ARSWER 16 OF 21 CAPLUS COPYRIGHT 1996 ACS
 1993:662341 Document No. 119:262341 Conformationally restricted
 sumatriptan analogs, CP-122,268 and CP-122,638 exhibit enhanced
 potency against neurogenic inflammation in dura mater. Lee, won
 Suk; Moskowitz, Michael A. (Stroke Research Laboratory, Neurosurgery
 and Reurology Services, Massachusetts General Hospital, Harvard
 Medical School, 32 Fruit Street, Boston, MA, 02114, USA). Brain
 Res., 626[1-2], 303-5 (English) 1993. CODEM: BREEAP. ISSN:
 0006-8993.

 AB CP-122,268 and CP-122,638 (analogs of sunatriptan in which the
 C3-aninocthyl side chain has been modified) blocked plasma protein
 extravasation response within dura mater following tripesinal
 ganglion stimulation. The threshold (1 and 0.1 mon/kg), resp.) was
 remarkably lower than for sunatriptan (7 mon/kg), as was the dose
 at max. response. As with sumatriptan, substance P-induced plasma
 leakage was unaffected by either compd., and metergoline only
 partially (27k) reversed the effects of CP-122,268. The data
 suggest the importance of modifications at the aninocthyl side chain
 to the actions of sumatriptan and possibly to the treatment of
 migraine headache.

 II 143321-74-8, CP 122268 143321-78-2, CP 122638
 RL: 8101 (Biological study)
 (neurogenic pachymeningitis-inhibition by, structure in relation
 to)

- ANSWER 18 OF 21 CAPLUS COPYRIGHT 1996 ACS AMSWER 18 OF 21 CAPLUS COPYRIGHT 1996 AC 1168927 Document No. 138:168927 Document No. 138:168927 Synthesis of a conformationally restricted analog of the anti-migraine drug sumatriptan. Macor, John E.; Blank, David Nr. Post, Ronald J.; Ryan, Kevin (Cent. Res. Div., Pfizer Inc., Groton, CT, G0340, USA). Tetrahedron Lett., 33(52), 8011-41 (English) 1992. CODEN: TELEAY. ISSN: 0040-4039. OTHER SOURCES: CASREACT 118:168927.
- The synthesis of conformationally restricted sumatriptan analog I (R = Me) (II) is described. The Mitsunobu coupling of hydroxypropene III (CBZ = benzyloxycarbonyl) with trifluoroacetanilide IV in the presence of Ph3P and DEAD gave Of X intermediate V, which underwent an intramol. Heck reaction with Pd(OAC)2 in the presence of EL3N in DWF to give 81% protected analog I (R = CBZ). A bonus of the latter cyclization was the concomitant loss of the trifluoroacetyl group. I (R = CBZ) was reduced with tIAHA4 in refluxing IMF gave 65% II. III was prepd. from pyrolidine VI in 4 steps, whereas IV was prepd. from 94-02/NC6H4CHZCI in 6 steps.
- IT 143321-74-8P

- II 143322-74-8F
 RL: SPM (Synthetic preparation); PREP (Preparation)
 (prepn. and antimigraine activity of)
 II 143321-82-8P
 RL: RCT (Reactant); SPM (Synthetic preparation); PREP (Preparation)
 (prepn. and hydride redn. of)

ANSWER 17 OF 21 CAPLUS COPYRIGHT 1996 ACS AKSWER 17 OF 21 CAPLUS COPPRIGHT 1996 ACS
169833 Document No. 119:249833 Indole derivatives which are
potent serotinin receptor antagonists. Macor, John E. (Pfizer Inc.,
USA), PCI Int. Appl. WO 9311105 A1 930610, 65 pp. DESIGNATEO
STATES: N: AU, BR, CA, CS, DE, FI, HU, JP, KR, NO, PL, RU, UA, US;
RN: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, II, LU, MC, NI, SE.
(English). CODEN: PIXXOZ. APPLICATION: WO 92-US8306 921006. PRIORITY: US 91-796744 911125.

AB The title compds. 1 [R] = CHZCHZMRZR8, Q], Q2 (dotted line represents an optional double bond), etc.; RZ,RS = H, Cl-Galkyl, aryl, Cl-3alkylaryl, etc.; x O, MH, S; Z = (un)substituted 5- or 6-membered heterocycleo; RZR8 may form a 4- to 6-membered ring], which are potent serotonin (S-HTI) receptor antagonists (no data), useful in the treatment of hypertension (no data), depression (no data), anxiety (no data), eating disorders (no data), obesity (no data), etc., are prepd. Thus, (R)-5-mino-3-(pyrrolidin-2-ylmethyl)-1-H-indole was prepd. by hydrogenolysis of (R)-3-(R-benzyloxycarbonylpyrrolidin-2-ylmethyl)-5-dibenzylamino-1H-indole.

II 443321-59-8P 183322-01-4P 181272-289-7P 181273-08-9P 181273-01-151273-02-8P 181273-03-9P 181273-03-1P 181273-03-1P 181273-03-1P 181273-03-1P 181273-03-1P 181273-03-1P 181273-03-1P 181273-13-P 181273-14-P 181273-13-1P 181273-13-

RL: RCT (Reactant)
(reaction of, in prepm. of indole serotomin receptor antagomist)

ARSWER 19 0F 21 CAPLUS COPYRIGHT 1996 ACS
:571215 Document No. 117:171215 Preparation of
3-(heterocyclylmethyl)Indoles as drugs. Macor, John Eugene; Wythes
Martin James (Pfizer inc., USA). PCT Int. Appl. NO 9206973 A1
920490, 82 pp. OSIGMAIED STATES: N: AU. BG, BR, CA, CS, DE, FI,
HU, JP, KR, NO, PL, NO, SU, US; RN: A1, BE, BR, BJ, CF, CG, CH, CI,
CH, DE, DX, ES, FR, CA, GB, GR, IT, LU, ML, MR, ML, SE, SM, TD, TG.
(English). CODEN: PIXXOZ. APPLICATION: NO 91-US7194 911008.
PRIORITY: US 90-597928 901015.

AB Title compds. I [n = 0-2; R2 = H, halo, cyano, R40 (wherein R4 = H, C1-6 alkyl, aryl), R6R5HCO(CH2)n, R6R5HSOZ(CHZ)n (wherein R5, R6 = H, C1-6 alkyl, aryl, C1-3 alkylaryl, R5R6 = 4-6-membered ring), R8COMR(CH2)n (S20MZ)(CH2)n, Wherein R7, R8 = H, C1-6 alkyl, aryl, C1-3 alkylaryl), R8(0)x5(CH2)n, R6R5HCOKR7(CH2)n, R9OZCHR7(CH2)n, R9CSCHR7(CH2)n, R9CSCHR7(CH2)n, R9CSCHR7(CH2)n, R9CSCHR7(CH2)n, R9CSCHR7(CH2)n, R9CSCHR7(CH2)n, R9CSCHATCH, RESCHATCH, RESCHATCH, RESCHATCH, RESCHATCH, RESCHATCH, RESCHATCH, RE

(hydrogenation of, in prepn. of serotonin agonist)
IT 143322-46-7P

```
ARSWER 19 OF 21 CAPLUS COPPRIGHT 1996 ACS
143322-10-5P 143322-11-6P 143322-12-7P
143322-10-5P 143322-11-6P 143322-12-0P
143322-16-1P 143322-17-2P 143322-18-0P
143322-16-1P 143322-17-2P 143322-18-0P
143322-13-2P 143322-23-0P 143322-24-1P
143322-23-5P 143322-23-0P 143322-24-1P
143322-31-6P 143322-39-6P 143322-31-2P
143322-31-6P 143322-31-2P 143322-31-2P
143322-31-6P 143322-31-2P 143322-31-6-5P
143322-31-6P 143322-31-6P 143322-31-6-5P
143322-31-6P 143322-41-2P 143322-31-6-5P
143322-43-4P 143322-44-5P 143322-45-6P
143322-43-4P 143322-44-5P 143322-45-6P
143322-50-3P 143322-51-4P 143322-52-5P
143322-50-3P 143322-51-4P 143322-52-5P
143322-50-6P 143322-51-4P 143322-52-5P
143322-51-6P 143322-52-7P 143322-60-6P
143322-51-6P 143322-52-7P 143322-60-6P
143322-51-7P 143322-50-9P 143322-60-6P
143322-51-7P 143322-60-6P 143322-60-6P
                                                                                                                                                                                                                                                                                                                                                                                                                            (Continued)
                     #3977-03-19
RX: BAC (Blological activity or effector, except adverse); SPM
(Synthetic preparation); IBU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as drug)
```

L7 ANSWER 21 OF 21 CAPLUS COPYRIGHT 1996 ACS
1974:59926 Document No. 80:39926 1,2,4a,5,6,8,9,14,14a,14bdecahydrobent[a]indolo[2,3-g]quinolizin-3(4h)-ones. Morrison, Glenn
C.; Shavel, John, Jr. (Warner-Lambert Co.). U.S. US 372306 731113,
3 pp. (English). CODEM: USXXAM. APPLICATION: US 71-202570 711126.
AB Ine title compd. (1) was prepd. by cyclizing 1,2,3,4-tetrahydro-1-(3indolylaethyl)-6-methoxyisoquinoline with CM20 to give
5,6,8,9,14,14a-hexahydro-3-methoxybenz[a]indole[2,3-g]quinolizine,
followed by oxidn. to 1,5,6,8,9,14,14a,14boctahydrobenz[a]indolo[2,3-g]quinolizin-3(2H)-one and redn. of the
4,4a-double bond. 1 are antihypertensive.

II 13118-20-2 IT 13118-20-2 8-20-2 : RCT (Reactant) (reaction of, with formaldehyde)

2 SEA FILE=CAPREVIEWS L4

L8

L7 ANSMER 20 OF 21 CAPLUS COPYRIGHT 1996 ACS 1991:185267 Document No. 114:185267 Preparation of indoles and analogs as doparine agonists and antihypertensives. Brubaker, Abrau (Research Corp. Technologies, Inc., USA). US. US. US. 4973593 A 901127, 17 pp. (English). CODEH: USXXAM. APPLICATION: US 87-81428 8730764

AB The title compds. I (Ar = ary), heteroary), etc.; R1 = H, alky), cycloalky), OH, alkoxy, etc.; R, R2 = H, alky), ary); R3, R4 = H, alky), OH, alkoxy, amino, etc.; n1 = 0 or 1; n2 = 0-3; X1, X2 = 0, CH, S, etc.) were prepd. I possess peripheral dopamine agonist activity and are devoid of any central dopamine stimulating activity. I are inactive at dopamine receptors in the brain. I are potent anthypertensives (no data). A mixt. of Et 6-[[4-(p-toly)sulfony])indoly]methy]-1,4-dioxa-7-azaspiro(4.5]decane-7-carboxylate and tiAlHH in HF was refluxed for 12 h to give 6-(4-indoly)methy]-7-methyl-1,4-dioxa-7-azaspiro(4.5]decane, which exhibited IDSO of 0.095 mol/kg in the cat cardioaccelerator assay (CCA). (CCA is used for evaluation of dopamine agonist activity).

Il 313132-68-09
R1: RCI (Reactant): SPM (Synthetic preparation): PDEP (Preparation)

3333-08-07 RL: RCI (Reactant); SPM (Synthetic preparation); PREP (Preparation) (prepn. and reaction of, in prepn. of antihypertensive and peripheral dopamine agonist) IT 133332-64-6P

J3332-04-0F RL: SPM (Synthetic preparation); PREP (Preparation) (prepn. of, as antihypertensive and peripheral dopamine agonist)

AMSWER 1 DF 2 Capreviews COPYRIGHT 1996 ACS 95:656780 Capreviews
The in vivo pharmacological profile of a 5-HII receptor agonist, CP-12Z,268, a selective inhibitor of neurogenic inflammation Gupta, P.; Brown, D.; Butler, P.; Ellis, P.; Grayson, K. L.; Land, G. C.; Nacor, J. E.; Robson, S. F.; Wythes, N. J.; Shepperson, N. B. Departments of Discovery Biology and Discovery Chemistry, Pfizer Central Research, Sandwich, Kent, CII3 9NJ, UK
Br. J. Pharmacol. (1995), 116(5), 2385-90
CODEN: BJPCBM; ISSN: 0007-1188
Journal

50

DT LA AB

CODEM: BJPCBW; ISSN: 0007-1188

Journal
English
The aim of the present study was to investigate the in vivo
pharmacol, profile of CP-122,288, an indole-derly, with a
conformationally restricted N-methylpyrrolidinyl basic side chain in
the C-3 position. This C-3 substituent structurally differentiates
CP-122,288 from the S-HIID receptor agonist sumatriptan, which
possesses an N,M-dimethylantnoethyl group. When administered prior
to elec, stimulation of the trigeminal ganglion, CP-122,288 (0.3-300
ng kg-1, 1.v.) produced a dose-related inhibition of plasma protein
extravasation in rat dura mater (min. ED, NED, 3 ng kg-1 1.v., P <
0.05; maximal inhibition of plasma extravasation at 30 ng kg-1 1.v., P <
0.05; maximal inhibition of plasma extravasation at 30 ng kg-1 1.v.,
P < 0.01). Sumatriptan produced a statilar inhibition of plasma
leakage in the dura, but at much higher dose levels (NED, 100, mu,
kg-1 1.v., P < 0.05). Thus, CP-122,288 is of the order of 104 fold
more potent than sumatripan. At all doses tested, CP-122,288 did
not inhibit plasma protein extravasation measured in extracranial
tissues such as the lower lip, eyelid, and conjunctiva. In a sep,
series of studies in the anesthetized rat, CP-122,288 (0.003-3 mu,
kg-1 1.v.) produced no change in either heart rate or mean arterial
blood pressure, thus demonstrating that doses of CP-122,288 which
inhibit plasma protein leakage in rat dura, are devoid of
hemodynamic effects. Following a 5 min period of sets. stimulation
of the trigeninal ganglion, a 20 min period of sustained
neurogenically-driven plasma extravasation, occurring in the absence
of elec. stimulation, was initiated. By addinistration of the
compd. 5 min after completing the phase of elec. stimulation, this
protocol permitted the evaluation of the activity of CP-122,288 on
the ongoing and established inflammatory event. CP-122,288 (30 and
300 ng kg-1, 1.v., produced a dose-dependent redn. in carotid arterial
blood flow and coronary arterial dida. These data demonstrate that
sumatriptan inhibits

08/466,644

Page · 38

L8 ANSWER 1 OF 2 CApreviews COPYRIGHT 1996 ACS (Continued)

=> d que 19

L9

1 SEA FILE=REGISTRY 143321-74-8/RN

=> d sub can

,

•

Page 40 08/466,644

L9 ARSWER 1 OF 1 REGISTRY COPYRIGHT 1996 ACS
RM 143321-74-8 REGISTRY
CM 1H-Indole-5-methanesulfonaside, M-methyl-3-{(1-methyl-2-pyrrolidinyl)methyl]-, (R)- (9CI) (CA INDEX MAME)
OTHER MAMES:
CM CP 122285
SS SIECROSEARCH
NF C16 H23 N3 02 S
SR CA
CL SIM Files: CA, CANCERLIT, CAPLUS, CAPREVIEWS, CASREACT,
CHEMINFORMEX, MEDLINE, TOXLIT
DES 1:R

Absolute stereochemistry.

1 REFERENCES IN FILE CAPREVIEWS 8 REFERENCES IN FILE CA (1967 TO DATE) 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 124:688

REFERENCE 2: 122:306133

REFERENCE 3: 122:256183

REFERENCE 4: 122:205025

REFERENCE 5: 122:64328

REFERENCE 6: 119:262341

REFERENCE 7: 118:168927

REFERENCE 8: 117:171215